

1 **Systems-wide dissection of organic acid assimilation in *Pseudomonas aeruginosa* reveals a**
2 **novel path to underground metabolism**

3 Stephen K. Dolan¹□, Andre Wijaya², Michael Kohlstedt³, Lars Gläser³, Paul Brear⁴, Rafael
4 Silva-Rocha⁵, Christoph Wittmann³ and Martin Welch⁴□

5 ¹School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332;
6 Emory–Children’s Cystic Fibrosis Center, Atlanta, GA 30322;
7 Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA
8 30332.

9 ²Centre for Targeted Protein Degradation, University of Dundee, Dow Street, Dundee, DD1
10 5EH, Scotland, United Kingdom

11 ³Institute of Systems Biotechnology, Saarland University, Saarbrücken, Germany

12 ⁴Department of Biochemistry, University of Cambridge, United Kingdom

13 ⁵Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brazil

14 □ Authors to whom correspondence should be addressed. MW (mw240@cam.ac.uk), SKD
15 (sdolan31@gatech.edu)

16
17 Running title: **The *P. aeruginosa* 2-methylcitrate cycle**

18
19 Keywords: ***Pseudomonas aeruginosa*, enzyme promiscuity, 2-methylcitrate cycle, central**
20 **metabolism, propionate metabolism, underground metabolism**

23 **Abstract**

24 The human pathogen *Pseudomonas aeruginosa* (Pa) is one of the most frequent and severe
 25 causes of nosocomial infection. This organism is also a major cause of airway infections in
 26 people with cystic fibrosis (CF). Pa is known to have a remarkable metabolic plasticity,
 27 allowing it to thrive in diverse environmental conditions and ecological niches, yet little is
 28 known about the central metabolic pathways which sustain its growth during infection, or
 29 precisely how these pathways operate. In this work, we used a combination of ‘omics
 30 approaches (transcriptomics, proteomics, metabolomics and ¹³C-fluxomics) and reverse
 31 genetics to provide a systems-level insight into how the infection-relevant organic acids,
 32 succinate and propionate, are metabolized by Pa. Moreover, through structural and kinetic
 33 analysis of the 2-methylcitrate synthase (PrpC) and its paralogue, citrate synthase (GltA), we
 34 show how these two crucial enzymatic steps are interconnected in Pa organic acid
 35 assimilation. We found that Pa can rapidly adapt to the loss of GltA function by acquiring
 36 mutations in a transcriptional repressor, which then de-represses *prpC* expression. Our
 37 findings provide a clear example of how ‘underground metabolism’, facilitated by enzyme
 38 substrate promiscuity, “rewires” Pa metabolism, allowing it to overcome the loss of a crucial
 39 enzyme. This pathogen-specific knowledge is critical for the advancement of a model-driven
 40 framework to target bacterial central metabolism.

41

42

43

44

45

46

47 **Introduction**

48 *Pseudomonas aeruginosa* (Pa) is a notorious opportunistic human pathogen that
49 frequently infects the airways of people with cystic fibrosis (pwCF). Pa is also well known for
50 being metabolically flexible. This flexibility is important because nutrient acquisition and
51 assimilation during infection scenarios is likely to be complex and dynamic process. Indeed,
52 there is an increasing realisation that the enzymes of metabolism may also serve as targets
53 for the next generation of antimicrobial therapies (1). However, we currently lack a clear
54 understanding of how core metabolism operates in Pa.

55 Laboratory strains of Pa are known to prefer C4-dicarboxylates such as malate,
56 fumarate and succinate as carbon and energy sources during growth *in vitro* (2). However,
57 for reasons that are not yet clear, during infection, Pa frequently uses less-favoured carbon
58 sources for growth, including the host-derived airway surfactant, phosphatidylcholine (PC).
59 This phospholipid is broken down by secreted Pa phospholipases to yield phosphorylcholine,
60 glycerol, and long-chain fatty acids (3, 4).

61 Pa can also metabolize short chain fatty acids. Propionate is a naturally-occurring
62 short-chain fatty acid produced by the human gut microbiota, and is a commonly used food
63 preservative with potent bacteriostatic activity. Another rich source of propionate are the
64 anaerobes that frequently occupy in the lower airways of pwCF. These anaerobes break
65 down tracheobronchial mucin to produce copious quantities of propionate. However, and in
66 spite of its known growth-inhibitory properties against some species of bacteria, Pa is able
67 to thrive on propionate, and can very effectively utilise the compound as a sole carbon
68 source *in vitro* (5–7). Pa does this by catabolising propionate through the 2-methylcitrate
69 cycle (2MCC) (**Figure 1A**) to yield succinate and pyruvate, which feed directly into the TCA

70 cycle. The 2MCC also sits at an important junction in amino acid catabolism, since several
71 amino acids (L-valine, L-isoleucine, L-methionine, and L-threonine) are degraded to
72 propionyl-CoA, which must then be oxidised by this pathway (7). Given the ubiquity of
73 propionate in many host niches, it comes as little surprise that a functional 2MCC is required
74 for infection by a plethora of human pathogens, including *Mycobacterium tuberculosis*,
75 *Neisseria meningitides* and *Aspergillus fumigatus* and *Talaromyces marneffe* (8–12). The Pa
76 2MCC has also been shown to be important for infection of the nematode intestine (13).

77 We currently have a limited understanding of how Pa metabolises propionate, or
78 how the 2MCC interfaces with the other components of central carbon metabolism in this
79 organism. Although some features of the pathway can be extrapolated from a knowledge of
80 the biochemistry in other bacteria (such as *Escherichia coli* and *Salmonella enterica*) these
81 are fundamentally dissimilar microbes with alternative operonic arrangements for the 2MCC
82 ORFs, and very different metabolic architectures compared with Pa (14, 15). For example,
83 propionate metabolism in several *Enterobacteriales* (including *E. coli* and *S. enterica*) and all
84 analysed *Xanthomonadales* is coordinated by a Fis family transcription factor (TF) known as
85 PrpR (16). By contrast, the 2MCC in *Gammaproteobacteria* is typically controlled by a GntR
86 family TF. Remarkably, no 2MCC regulators from the GntR family have been experimentally
87 characterised to date. Therefore, and to understand better how Pa utilizes propionate, we
88 used a combination of ‘omics approaches (transcriptomics, proteomics, metabolomics and
89 ¹³C-fluxomics) and reverse genetics to provide a systems-level insight into how the organic
90 acids, succinate and propionate, are metabolized by Pa. Moreover, through structural and
91 kinetic analysis of the 2-methylcitrate synthase (PrpC), and its paralogue citrate synthase
92 (GltA), we show how these two crucial steps are interconnected in organic acid assimilation.
93 Building on these observations, we found that Pa can rapidly adapt to the loss of GltA by

acquiring mutations that de-repress expression of the *prpC*-encoding 2MCC operon (*prp*). These mutations are in a GntR-family TF, which we show encodes a transcriptional repressor of the *prp* operon. Our findings provide a clear example of how ‘underground metabolism’ (17), facilitated by enzyme promiscuity, allows *Pa* to overcome the loss of a crucial enzyme in central carbon metabolism.

Results

‘Omics-driven examination of *Pa* grown on succinate and propionate as sole carbon sources.

To understand how growth on different substrates affects the physiology of *Pa*, we first examined the proteome during exponential phase growth on succinate or on propionate as a sole carbon source. Through the proteomic analysis, we identified and quantified 3796 proteins. Of these, 265 proteins showed increased abundance during growth on propionate, and 295 proteins showed increased abundance during growth on succinate (q -value ≤ 0.05 , $\log_2$ fold-change ≥ 1 or ≤ -1 ; **File S1**). To obtain a global overview of the physiological changes, we used the Proteomaps web service (18) to generate Voronoi tessellations (19) structured around the KEGG orthologies of the statistically significant changes (p -value ≤ 0.01 , $\log_2$ fold change ≥ 1 or ≤ -1). As shown in **Figure 1B**, most of the proteomic changes were associated with ‘central carbon metabolism’, ‘biosynthesis’, ‘signalling and cellular process’ and ‘energy metabolism’. Notably, growth on propionate led to a strong induction (ca. 16-fold change (FC)) of all proteins encoded by the *prp* operon, including the GntR-family 2MCC operon regulator, PA0797, which we designate here as PrpR (**Figure S1A-D, File 1A**).

To provide a complementary insight into the absolute metabolic fluxes in Pa during growth on propionate and succinate, we also carried out a [^{13}C] fluxome analysis. This was achieved by measuring the mass isotopomer distributions in proteinogenic amino acids and cell carbohydrates using three separate tracers for propionate and succinate (*Materials and Methods*) (20). The calculated relative fluxes for Pa strain PAO1 grown on labelled propionate or succinate are shown in **Figure 2**. The corresponding quantitative comparison of NADPH (redox) supply and ATP (energy) supply for succinate- and propionate-grown Pa are shown in **Figure S2**.

Comparison of the flux maps, in combination with the proteomic data, generated an unparalleled insight into the central carbon metabolic networks of Pa during growth on both substrates. For example, several of the key proteomic alterations found when comparing growth on propionate with growth on succinate were in core central carbon metabolism (**File S1A**). These core changes were largely consistent with the corresponding carbon flux distributions (**Figure 2**). In general, the expression of enzymes from the pentose phosphate pathway (PPP), the Embden-Meyerhof-Parnas pathway (EMPP) and the Entner-Doudoroff pathway (EDP) was decreased during growth in propionate compared with succinate. The expression of several enzymes in the TCA cycle were increased during growth on propionate, including citrate synthase GltA (2.5 FC), aconitase AcnA (2.3 FC) and the isocitrate dehydrogenases ICD (2.5 FC) and IDH (1.7 FC). A corresponding increase in TCA cycle carbon flux was also evident, with roughly an 11% increase in flux through the reactions between citrate (CIT) and malate (MAL) (**Figure 2**). Fumarate efflux (2%) was also detected during Pa growth using succinate as a sole carbon source.

Among the largest discrepancies between the propionate- and succinate-grown cultures at both the proteome and fluxome level were noted at the reactions involved in the pyruvate shunt. Expression of the malic enzyme, MaeB, which catalyses the oxidative decarboxylation of malate to produce pyruvate and CO₂, was down-regulated (-4.7 FC) during growth on propionate. By contrast, the pyruvate carboxylase-encoding proteins, *pycA* (PA5435) and *pycB* (PA5436), which catalyse the ATP-dependent carboxylation of pyruvate to yield oxaloacetate, were up-regulated (2.6 FC), as was the regulator, PycR (21, 22). These alterations matched the corresponding flux data, which revealed a substantial decrease in flux from malate to pyruvate (-87%) and an increase in the flux from pyruvate to oxaloacetate (OAA) (54%) during growth on propionate. There is a good metabolic logic to this. Although the catabolism of propionate yields succinate and pyruvate, an early enzyme in the propionate catabolic pathway (PrpC) requires oxaloacetate as a substrate (**Figure 1**). Therefore, we hypothesised that this drain on the oxaloacetate pool may be countered by a combination of lower malic enzyme-mediated pyruvate generation and increased anaplerotic pyruvate carboxylase activity to sustain the TCA cycle. In support of this, mutants defective in pyruvate carboxylase (encoded by *pycA* and *pycB*) were unable to grow on propionate as a sole carbon source (**Figure S1E**). Growth on propionate also increased the expression (5.1 FC) of the membrane-bound malate-quinone oxidoreductase, MqoB, which generates oxaloacetate directly from malate. A corresponding 98% increase in carbon flux from malate to oxaloacetate was evident during growth on propionate (**Figure 2**).

The expression level of phosphoenolpyruvate synthase (PPS) and pyruvate kinase showed no significant differences between the growth conditions. However, the fluxomic analysis captured a pronounced alteration in carbon flow at this node. During growth on succinate, the net carbon flux was in the pyruvate → phosphoenolpyruvate (gluconeogenic)

direction, with phosphoenolpyruvate originating from pyruvate mainly *via* the combined activity of malic enzyme (MAE) and PEP synthase at the equivalent cost of 2 ATP ($\text{PYR} + \text{H}_2\text{O} + \text{ATP} \rightarrow \text{PEP} + \text{AMP} + \text{P}_i$). By contrast, during growth on propionate, the net flux at this node was in the direction phosphoenolpyruvate $\rightarrow$ pyruvate; a reaction that is catalyzed by pyruvate kinase isozyme A (PykA) and that generates ATP (23). In this scenario, phosphoenolpyruvate largely originates from the action of phosphoenolpyruvate carboxykinase (PckA) on the oxaloacetate that is generated *via* the activity of malate-quinone oxidoreductase (MqoB). Interestingly, and despite the greatly increased flux from oxaloacetate $\rightarrow$ phosphoenolpyruvate catalyzed by PckA, the expression of this enzyme was decreased 1.7-fold during growth on propionate compared with growth on succinate. This may indicate a role for allosteric regulation in modulating PckA enzyme activity (24, 25).

When compared with growth on succinate, the glyoxylate shunt enzymes, *isocitrate* lyase (AceA; 5.5 FC) and malate synthase (GlcB; 3.6 FC) were highly expressed on propionate. This was also verified using promoter-luciferase transcriptional fusions (**Figure S1F-I**). However, the fluxomics data indicated that there was no carbon flux through the glyoxylate shunt during growth on either succinate or propionate as a sole carbon source. This may be explained by the extensive allosteric interactions which are known to control flux partitioning between the TCA cycle and glyoxylate shunt. *Isocitrate* lyase (ICL) activity in Pa is allosterically inhibited by oxaloacetate, pyruvate, succinate, phosphoenolpyruvate (PEP), and CoA. By contrast, oxaloacetate and pyruvate allosterically activate one of the *isocitrate* dehydrogenase enzymes, IDH (26). As flux to pyruvate is significantly increased during growth on either succinate or propionate compared with acetate (where flux through the glyoxylate shunt is maximal), these data suggest that pyruvate is the most likely

metabolite responsible for abrogating flux through the glyoxylate shunt during growth on propionate (27).

Several studies have suggested that simple diffusion across the cytoplasmic membrane is the predominant mechanism of both acetate and propionate uptake in bacteria (28, 29). One cluster of ORFs (PA3232-PA3235) were up-regulated (ca. 16 FC) during growth on propionate, and encode a putative acetate permease (ActP). Indeed, PA3234 shows 80% amino acid identity to the ActP protein from *Escherichia coli*, and this ORF has been previously shown to be regulated by the two component system, MxtR/ErdR, which is essential for growth on acetate (30, 31). MxtR was also up-regulated during growth on propionate (8.7 FC), whereas proteins associated with dicarboxylic acid transport (DctA, DctQ, DctP and PA5530) were more abundant during growth on succinate (**File S1A**) (32, 33).

Aerobic growth in different carbon sources results in large-scale remodelling of the electron transport chain in Pa, including components of the denitrification pathway (27). Growth on propionate led to significantly increased expression of most terminal oxidases, particularly the quinol oxidase Cyo (7.6 FC), the cyanide-insensitive oxidase Cio (5.4 FC), the cytochrome c oxidase Cco2 (3.0 FC) and the cytochrome oxidase Cox (2.2 FC). Furthering the notion of an altered redox balance during growth on the two substrates, we noticed differences in expression of the NAD(P) transhydrogenases, which fine-tune the size and degree of reduction of the nicotinamide adenine dinucleotide pools (34). Expression of the transhydrogenase Sth (PA2991) which is thought to primarily convert NADPH → NADH, was increased during growth on propionate (2.1 FC), whereas the transhydrogenase proteins PntAA (3.6 FC) and PntB (2.2 FC) (which presumably catalyze the interconversion NADH → NADPH) were more abundant during growth on succinate. These alterations were reflected

in the redox balances; growth on propionate resulted in a lower NADPH surplus (as any excess is assumed to be converted to NADH to drive ATP synthesis) when compared with growth on succinate (**Figure S2**).

The 2MCC also serves a role in the catabolism of branched chain amino acids (BCAA). This is because *isoleucine* and *valine* degradation generates propionyl-CoA, which can then be degraded to succinate and pyruvate *via* the 2MCC (35). The metabolism of *valine* produces the intermediate (S)-3-hydroxyisobutyric acid which is oxidized to methylmalonate semialdehyde by 3-hydroxyisobutyrate dehydrogenase (MmsB). Methylmalonate semialdehyde dehydrogenase (MmsA) then catalyses the irreversible NAD⁺- and CoA-dependent oxidative decarboxylation of the semialdehyde to yield propionyl-CoA (35, 36). MmsB (28.1 FC) and MmsA (5.3 FC) expression were significantly increased during growth on propionate. This suggests that there is a regulatory link between the 2MCC and BCAA catabolism in *Pa*.

Propionate inhibits the growth of *Pa* when propionate catabolism is disrupted

Based on the proteomics data, we made (separate) in-frame deletions in a selection of genes putatively involved in propionate uptake (PA3234 – the *actP* homologue), propionate activation (*acsA*, PA3568) and propionate catabolism (*prpC*, *mmsA*, *aceA*, *glcB*) and tested the ability of the resulting mutants to grow on a series of single carbon sources (**Figure 3A, Figure S3A-C**). Importantly, the acetyl-CoA synthetase mutant ($\Delta acsA$) exhibited a pronounced growth defect with either acetate or propionate as a sole carbon source, suggesting that activation of propionate is carried out primarily by this enzyme (**Figure S3B,C**). By contrast, the $\Delta PA3568$ mutant (defective in another potential propionyl-CoA synthetase) and the putative acetate symporter ($\Delta PA3234$) mutant had no growth

phenotype in any of the conditions tested. Similarly, the mutants defective in *mmsA*, *aceA*, or *glcB* also exhibited no growth defects on propionate, despite significant up-regulation of the corresponding gene products during growth on this carbon source. Notably, the 2-methylcitrate synthase mutant ($\Delta prpC$) was unable to grow on propionate as a sole carbon source but displayed no detectable growth deficit on any of the other tested carbon sources.

In the absence of a functional 2-methylcitrate synthase (PrpC), the accumulation of intracellular propionyl-CoA, either through direct catabolism of propionate or through catabolism of branched chain amino acids, has been proposed to have growth inhibitory properties for several microorganisms (37–39). As shown in **Figure 3B**, when propionate (5–20 mM) is added to LB agar, growth of the $\Delta prpC$ mutant becomes progressively more inhibited as the concentration of propionate increases. The growth inhibitory effect of propionate on the $\Delta prpC$ mutant was also apparent when propionate was added to MOPS-buffered succinate, ruling out pH dependent toxicity (**Figure S3D**). Notably, the $\Delta prpC$ mutant was also unable to grow on branched chain amino acids as a sole carbon source (**Figure S3E**). To examine this possible growth inhibition by propionyl-CoA further, we exposed PAO1 and the $\Delta prpC$ mutant to 5 mM propionate during exponential growth on succinate (25 mM). Then, after a further 3 h of growth, we measured the intracellular propionyl-CoA levels in each sample (**Figure 3C**). This revealed that even during growth on a preferred carbon source, succinate, propionyl-CoA accumulates in the $\Delta prpC$ mutant compared with wild-type PAO1.

We previously characterized the metabolic pathways expressed in Pa during growth on acetate (27). Comparison of those data with the results presented here for growth on

propionate revealed several commonalities, including increased expression of *AcsA*, PA3234 (the *actP* homologue), and the glyoxylate shunt enzymes on acetate and propionate. This may reflect the activity of shared regulators, or analogous reaction mechanisms and overlapping substrates (**Figure 3D**). As shown in **Figure S3F** and consistent with the fluxomics data (which revealed negligible flux through the glyoxylate shunt during growth on propionate), mutants defective in the glyoxylate shunt enzymes, $\Delta aceA$ and $\Delta glcB$, suffered no growth defect on propionate as a sole carbon source. As expected, the same mutants were unable to grow on acetate as a sole carbon source (**Figure S3F**). Remarkably, this growth of the $\Delta aceA$ and $\Delta glcB$ mutants on propionate was blocked when acetate was added to the media (**Figure 3E**). This growth inhibition could be partially relieved by increasing the concentration of propionate in the media, suggesting metabolic competition between acetate and propionate catabolism (**Figure 3E**). By contrast, acetate did not prevent growth of the $\Delta aceA$ and $\Delta glcB$ mutants on plates containing succinate (**Figure S3F**). In the absence of the glyoxylate shunt, acetyl-CoA generated through the activation of acetate or through β -oxidation of fatty acids is unable to contribute to *Pa* biomass generation. Since *AcsA* likely activates both acetate and propionate, a parsimonious hypothesis is that saturating concentrations of acetate (which is probably the preferred substrate of *AcsA*) competitively block the activation of propionate. This competition is relieved at higher propionate concentrations, thereby enabling growth of the $\Delta aceA$ and $\Delta glcB$ mutants.

Structural and functional investigation of PrpC and GltA from *Pa*

PrpC catalyzes the condensation of oxaloacetate and propionyl-CoA. In a parallel reaction, the TCA cycle enzyme, citrate synthase (*GltA*), catalyzes the condensation of

oxaloacetate and acetyl-CoA. Given the apparent promiscuity of AcsA with respect to acetate and propionate activation, we wondered whether the condensation of propionyl-CoA and acetyl-CoA with oxaloacetate could be carried out interchangeably by PrpC and GltA (**Figure 3D**). Indeed, PrpC from *E. coli* has secondary citrate synthase activity and overexpression of *prpC* in this organism can rescue the synthetic lethality of citrate synthase loss (40–43). To examine whether this is also the case in Pa, a Δ *gltA* mutant was generated. Colonies of the Δ *gltA* mutant on LB agar were visibly smaller when compared with wild-type PAO1 (**Figure 4A**). This phenotype could be partially complemented by supplementing the plates with glutamate, whose carbon skeleton enters the TCA cycle after the citrate synthase-catalyzed step (**Figure S4A**).

To assess directly whether PrpC_{Pa} has citrate synthase activity (and whether citrate synthase may also have 2-MC synthase activity), we purified each enzyme to investigate its specificity and kinetic properties *in vitro*. The Pa *prpC* and *gltA* genes were cloned and overexpressed (with cleavable His₆ tags) in *E. coli*, and purified to homogeneity. Each purified enzyme was then assayed for 2-methylcitrate synthase activity and citrate synthase activity. The PrpC enzymes from species including *S. enterica*, *E. coli*, and *B. subtilis* have previously been reported to exhibit a strong preference for propionyl-CoA compared with acetyl-CoA (42, 44, 45). However, PrpC_{Pa} displayed roughly comparable activity towards these acyl-CoAs, although $V_{\max}$ was greater with propionyl-CoA as a substrate (**Figure 4B, S4B**). The specificity (expressed as k_{cat}/K_M) of PrpC_{Pa} for propionyl-CoA was $104 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$, whereas for acetyl-CoA k_{cat}/K_M was $114 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$ (**Table S1C**). By contrast, and unlike GltA from *S. enterica* (which exhibits a low level of 2-methylcitrate synthase activity (46)), GltA from Pa (GltA_{Pa}) had no detectable 2-methylcitrate synthase activity (**Figure 4C**).

To gain insights into the possible structural bases for these kinetic data, we used x-ray crystallography to solve the structure of PrpC_{Pa} and GltA_{Pa} (**Figure 4D**). PrpC_{Pa} is a homodimer in both the crystal structure (**Figure 4D**) and in solution (**Figure S4D**), whereas the GltA_{Pa} asymmetric unit was comprised of a hexameric “trimer of dimers” (**Figure 4E**). Structural superposition of PrpC_{Pa} and GltA_{Pa} revealed a near-identical α -helical core fold (**Figure 4F**) with a C α RMSD of 1.33 Å. GltA_{Pa} is slightly larger than PrpC_{Pa} (429 amino acids *versus* 376 amino acids, respectively) and has an additional 50 amino acid residues at its N-terminus, which form four anti-parallel β -strands and loops (**Figure 4F**). In addition to solving the apo-structures of the enzymes, we also obtained the structure of PrpC_{Pa} with oxaloacetate bound in the active site (**Figure 5A**). The active site was located in a cleft between two domains on the enzyme. A comparison of PrpC structures from different bacterial species revealed that the residues comprising the PrpC_{Pa} active site are very highly conserved. For instance, in *S. enterica* His235 (His222 in PrpC_{Pa}), His274 (His 261 in PrpC_{Pa}), and Asp325 (Asp312 in PrpC_{Pa}) form a catalytic triad (45).

In the PrpC_{Pa} apo-structure (open conformation), each protomer in the asymmetric unit is identical (backbone RMSD of 0.23 Å from a total of 360 C α atoms). However, in the holo-PrpC_{Pa} structure, the conformation of one of the oxaloacetate-bound protomers (chain D) in the asymmetric unit was different. Each asymmetric unit comprised four monomers of PrpC_{Pa}, but only chain D contained an unambiguous electron density for oxaloacetate (**Figure 5B**). The other chains (chains A, B and C) had an identical conformation to those of apo-PrpC_{Pa}. Interestingly, the dimerization partner of chain D, chain C, (shown in orange in **Figure 5A**) had no oxaloacetate in its active site. This raises the possibility that PrpC_{Pa} exhibits half-of-the-sites reactivity, where only one-half of the identical subunits are active at any given time (47).

GltA_{Pa} has the essential catalytic triad of residues that are also found in the *Sus scrofula* citrate synthase; His265, His306 and Asp363 (Pa numbering). The side-chain orientation in this triad is identical in the majority of apo-PrpC and apo-GltA structures, including PrpC_{Pa} (**Figure 5C**). In *S. enterica* PrpC, Tyr197 and Leu324 (Tyr184 and Ala311 in PrpC_{Pa}) have been proposed to confer substrate specificity (45). The corresponding residues in the citrate synthases are histidine and valine (His227 and Val363 in GltA_{Pa}). However, the PrpC from *A. fumigatus* also has histidine and valine in these positions; hence, the precise role(s) of these residues in imparting substrate specificity are still not clear. In addition to binding its substrate, citrate synthase from *E. coli* also binds NADH, and may even be regulated by this compound. The residues important for NADH binding in GltA from *E. coli* are Met112 and Cys206 (44). These residues are also present in GltA_{Pa}, but they are absent from PrpC_{Pa}. This is consistent with the notion that GltA_{Pa} is probably regulated by NADH (48), whereas this is probably not the case for PrpC_{Pa}.

Superposition of the apo-PrpC_{Pa} and holo-PrpC_{Pa} structures highlights the conformational change associated with oxaloacetate binding (**Figure 5D**). The oxaloacetate-bound PrpC_{Pa} has a more compact configuration, achieved through a 2 Å (average) movement and 7° rotation of the associated domain toward the centre of the dimer. This conformation was also observed in the *Sus scrofa* citrate synthase, where it was described as a “partially closed conformation” (49). The fully closed conformation was observed when both oxaloacetate and Ac-CoA were bound to the enzyme (50). Compellingly, all acyl-CoA bound citrate synthase structures in the PDB contain either bound oxaloacetate or bound citrate. This suggests an ordered reaction sequence. Indeed, in citrate synthase, the binding of oxaloacetate has been biochemically and structurally demonstrated to bring about a

conformational change which appears to be critical for the subsequent binding of Ac-CoA (49). Presumably, a similar ordered reaction sequence is associated with PrpC_{Pa}. Consistent with the notion that oxaloacetate binding is accompanied by a conformational change in the enzyme, we observed increased thermal stability of PrpC_{Pa} upon the addition of oxaloacetate (**Figure S4C**).

Transcriptomics reveals how Pa responds to challenge with exogenous propionate

From the proteomic data, PrpC_{Pa} (and all other enzymes of the 2MCC) were detectable during growth of Pa on succinate as a sole carbon source, so it is possible that the 2MCC also serves a non-canonical, uncharacterised role(s) in Pa physiology. To explore this further, RNA-seq was used to (i) compare the transcriptome of wild-type PAO1 with that of an isogenic $\Delta prpC$ mutant during growth on succinate, and (ii) examine how the transcriptome is perturbed following exposure of succinate-grown cells to a sub-inhibitory concentration (500 μ M) of propionate (added during exponential growth (**Figure 6A, S5A-E**)).

Consistent with the proteomic data, appreciable *prpC* reads were detected in PAO1 during growth on succinate (**Figure S5B**). This basal expression of the 2MCC enzymes may benefit the cell by priming it ready for rapid propionyl-CoA detoxification/catabolism. Relatively few PAO1 transcripts showed substantial alterations in abundance compared with the $\Delta prpC$ mutant during growth on MOPS-succinate medium (**File S3, Figure S5D**). This suggests that the absence of a functional 2MCC does not lead to extensive transcriptional re-programming during *per se*. Transcripts encoding two enzymes (BkdA1, BkdA2) involved in branched chain amino acid (BCAA) catabolism were down-regulated in the $\Delta prpC$ mutant when compared with the wild-type during growth on succinate. However, this repression

was relieved upon exposure of the $\Delta prpC$ mutant to exogenous propionate (2.2 FC). These data indicate that in the wild-type, flux through the 2MCC during growth on succinate may produce low levels of propionate, and that this impacts on BCAA catabolic gene expression. The source of this propionate could be from the catabolism of endogenously produced, propionyl-CoA-generating amino acids or possibly through reverse operation of the 2MCC. The 2MCC has recently to be shown to be reversible in *M. tuberculosis* to allow optimal metabolism of lactate and pyruvate (51).

The most statistically-significant up-regulated transcripts in the wild-type following challenge with propionate were associated with ORFs PA3415-PA3417 (2.8 FC). These ORFs are predicted to encode a pyruvate dehydrogenase (PDH) or a branched chain amino acid dehydrogenase (**File 3, Figure 6B**) (52). Immediately adjacent to the PA3415-PA3417 cluster is leucine dehydrogenase (*ldh*, PA3418), required for BCAA catabolism, which was also significantly up-regulated upon propionate exposure. The same ORFs were also up-regulated in the $\Delta prpC$ mutant after propionate addition, indicating that full catabolism of propionate is not required as a cue to activate the expression of these genes (**File S3, Figure S5C**). However, given that propionyl-CoA is an intermediate in the metabolism of BCAA, these results likely indicate regulatory cross-talk between expression of the PA3415-PA3417-*ldh* cluster and expression of the enzymes involved in BCAA catabolism. Unexpectedly, *acsA* and PA3233-PA3235 (the ORF cluster that includes the ActP protein) which have putative roles, respectively, in propionate activation and transport, were down-regulated (-2.0 FC) in PAO1 upon propionate addition.

Pa responds to propionate exposure by increasing expression of the *prp* operon (**Figure 6B**). This up-regulation of the *prp* operon was blocked in the $\Delta prpC$ mutant (**Figure**

S5E, File S3). We further confirmed the induction of PrpB expression in response to propionate by western blotting (**Figure S5F**). However, this propionate-induced expression of PrpB was abolished in the $\Delta prpC$ mutant (**Figure S5F**). PrpB expression in response to propionate challenge was maintained in a $\Delta acsA$ mutant, suggesting that propionyl-CoA can also be generated from propionate through alternative routes in Pa. *AcsA* expression is known to be under the control of the response regulator, ErdR, and consistent with this, an $\Delta erdR$ mutant cannot grown on ethanol or acetate as a sole carbon source (53). Given the dual role that *AcsA* seems to play in acetate and propionate catabolism, we therefore examined whether a $\Delta erdR$ mutant also displays aberrant growth on propionate. It did (**Figure S5G-I**). Surprisingly, the growth deficit of the $\Delta erdR$ mutant on propionate was even more pronounced than that of a $\Delta acsA$ mutant. This indicates that additional downstream targets of ErdR, such as *ErcS*, *ErbR* or the ethanol oxidation system, may also be required for optimal propionate catabolism in Pa (54).

How is propionate assimilated in Pa and converted to propionyl-CoA, activating the 2MCC operon even when preferable carbon sources are readily available? Carbon catabolite repression (CCR) allows Pa to selectively assimilate a preferred compound when a selection of carbon sources are available. In Pa, CCR is controlled through translational silencing, mediated by Hfq and the small protein Crc (55). Reversing this translational silencing requires the small RNA (sRNA) *CrcZ*, which sequesters Hfq thereby preventing the latter from binding to target transcripts. *CrcZ* abundance is controlled by a two-component system, *CbrAB*, which senses and responds to carbon availability (55). In Pa, *acsA* mRNA harbours a sequence motif located upstream of the *acsA* start codon, which brings acetate assimilation under CCR control. Because they are impaired in *CrcZ* expression, mutants defective in *cbrB* exhibit a severe growth defect when grown on acetate as a sole carbon

source ((56) and **Figure S5I**). We found that a $\Delta cbrB$ mutant also had a clear growth defect on propionate (**Figure S5H**). However, since the $\Delta cbrB$ mutant maintained inducible PrpB expression upon propionate exposure (**Figure S5J**), this suggests that CCR does not exert direct control over the 2MCC, but may impact on propionate catabolism indirectly e.g., by affecting *acsA* expression and/or other peripheral targets.

Since CCR did not appear to be directly coordinating the expression of the 2MCC, this prompted us to examine in more detail the role of the GntR-family TF, PrpR (PA0797) in controlling *prp* gene expression. GntR family TFs are typically regulated by ligands that are metabolic substrates/products/cofactors associated with the products of the genes that they regulate (57). Previous studies in *Corynebacterium glutamicum* and *S. enterica* established that 2-methylcitrate (2-MC), the reaction product of PrpC, is a co-activator of the Fis-family PrpR in these species (58, 59). By contrast, PrpR from *M. tuberculosis* is a 4Fe4S protein that employs propionyl-CoA as a co-activator (60). Our observation, that the 2MCC is not induced upon exposure to propionate in a $\Delta prpC$ mutant (**Figure S5E,F**), is consistent with 2-MC rather than propionyl-CoA being the co-activator, especially given that propionyl-CoA accumulates in a $\Delta prpC$ mutant following propionate challenge (**Figure 3C**).

In contrast to all other species characterized to date, the $\Delta prpR$ mutant of Pa had no growth defect on any of the carbon sources tested (**Figure S5H-J**). This suggested that the canonical model of 2MCC regulation by PrpR established for other organisms does not apply in Pa. Remarkably, PrpB was over-expressed in the $\Delta prpR$ mutant during growth on succinate, independent of the presence or absence of propionate in the medium (**Figure 6C**). This suggested that Pa PrpR may actually be a *repressor* of the 2MCC, rather than an activator (58). Consistent with this, expression of *prpR* from a plasmid (pUCP20) in the $\Delta prpR$

mutant was sufficient to repress PrpC expression in this strain (**Figure S6A**). The predicted PrpR binding motif in Pa, identified by phylogenetic footprinting, is a 12-nucleotide palindrome with the consensus sequence ATTGTCGACAAT (16); this sequence is found upstream of PrpR (84 bp) in PAO1 and PA14. PrpR was recombinantly-expressed and purified to homogeneity (**Figure S6B**) for electrophoretic mobility shift analyses (EMSA; **Figure S6C**). These data revealed that PrpR does indeed bind to the upstream region of *prpR*.

Somewhat surprisingly, we found that a Pa citrate synthase mutant (Δ *gltA* – **Figure 4A**) could also grow on single carbon sources in minimal media, albeit with a prolonged lag phase. Given that PrpC_{Pa} can carry out the condensation of acetyl-CoA with oxaloacetate (**Figure 4B**) and can therefore potentially substitute for GlcA, we suspected that the viability of the Δ *gltA* mutant on single carbon sources might be explained by induction of *prpC*. Consistent with this, and despite repeated attempts at doing so, we were unable to make a Δ *gltA* Δ *prpC* double mutant. If our hypothesis is correct, and given that *prpC* expression is repressed by PrpR, we began to wonder whether *prpR* in the Δ *gltA* mutant might be under strong selection pressure to acquire loss-of-function mutations, thereby boosting PrpC expression. Commensurate with this, successive rounds of sub-culturing of the Δ *gltA* mutant in MOPS-succinate readily yielded heritable derivatives displaying a restoration of rapid growth in this medium. Furthermore, these “evolved” Δ *gltA* mutants also constitutively expressed PrpC and PrpB, independent of propionate addition (**Figure 6C, S6A**). A similar restoration of rapid growth in MOPS-succinate medium was observed when we deleted *prpR* in the Δ *gltA* background (**Figure S6D**).

But are loss-of-function mutations in *prpR* the most probable evolutionary path taken by the Δ *gltA* mutant to overcome its metabolic bottleneck? Alternative mechanisms could include mutation of the PrpR binding site upstream of the *prp* operon, duplication of *prpC*, or inactivation of one or more uncharacterized genes involved in modulating PrpR expression. To investigate this further, we made fresh deletions in *gltA* (to minimize the possibility of the strain acquiring additional mutations prior to passaging). Three independent Δ *gltA* mutant colonies were isolated and passaged in MOPS-succinate for two days; all three cultures displayed wild-type levels of growth after this time (**Figure 6D, S6D**). The three independently evolved Δ *gltA* mutants were sent for whole-genome sequencing alongside the wild-type progenitor (**Figure S6E**). Strikingly, each of the three evolved Δ *gltA* mutants (EVOL_1-3) had accrued distinct missense mutations in *prpR* giving rise to the amino acid substitutions V80L (EVOL_1) and R54H (EVOL_3) in PrpR, or a 6 bp deletion in *prpR* leading to the loss of amino acids L67 and R68 in PrpR (EVOL_2). These residues were mapped on to the AlphaFold-generated structure of PrpR, which indicated that they fall within and proximal to the conserved winged helix-turn-helix (wHTH) domain of this repressor – a region crucial for the DNA-binding in this family of transcription factors (**Figure 6E**) (61, 62). Indeed, mutation of residue R52 (equivalent to residue R54 in PqsR) in the *E. coli* MqsR-controlled colanic acid and biofilm regulator (McbR) results in a loss of DNA-binding (57). This provides clear evidence that in the absence of *gltA*, *prpR* is reproducibly mutated to facilitate *prpC* over-expression.

Discussion

We have carried out a systems-level characterisation of Pa during growth on succinate and propionate as sole carbon sources. This revealed previously undiscovered

transcriptional and metabolic crosstalk between several major metabolic pathways/cycles; the 2MCC, BCAA catabolism and the glyoxylate shunt. Our work also provides mechanistic insight into how enzyme promiscuity and regulatory rewiring can rapidly overcome the loss of a key enzyme in the TCA cycle, citrate synthase. We show that *Pa* can survive the loss of citrate synthase (GltA) through a combination of low, basal-level expression of PrpC, followed by acquisition of loss-of-function mutations in the transcriptional repressor *prpR*. This leads to a compensatory increase in secondary citrate synthase activity through PrpC over-expression (**Figure 7A-C**).

We found that *Pa* responds to propionate exposure by increasing expression of the *prp* operon. This propionate-dependent expression of the 2MCC was unaffected by carbon catabolite repression (CCR) or by deletion of the primary short-chain acyl-CoA synthetase, AcsA. This may reflect the established appetite of *Pa* for organic acids (1), but it could also be that the primary role of the 2MCC is in propionate detoxification, rather than routine carbon assimilation. It appears that *Pa* counters rapid propionyl-CoA generation by having an exceptionally responsive 2MCC which promptly degrades inhibitory metabolic intermediates. In *M. tuberculosis*, this detoxification is carried out by the constitutively expressed methylmalonyl-CoA (MMCO) pathway, which can quickly react to sudden changes in propionate concentration and detoxify the cell accordingly. By contrast, the role of the *M. tuberculosis* 2MCC appears to be as a “professional catabolizer”, with a higher overall flux capacity than the MMCO (63). The absence of a functional MMCO in *Pa* means that this organism depends exclusively on the 2MCC for both the assimilation and detoxification of propionate.

The trade-off between responsiveness to propionate and the accumulation of cytotoxic 2MCC intermediates is a structural weakness of this catabolic arrangement; a weakness that can potentially be exploited to fight *Pa* infections. Importantly, a synthetic PrpC inhibitor was bacteriostatic against *M. tuberculosis* grown in cholesterol media (cholesterol is broken down by *M. tuberculosis* to yield propionyl-CoA). This suggests that cell-permeable PrpC-specific inhibitors are indeed achievable (64). Considering the structural similarity between PrpC and GltA, it may be possible to generate an inhibitor which targets both enzymes simultaneously. This could be a powerful combination, as a transposon mutagenesis screen indicated that *gltA* is required for the growth of nine different *Pa* strains from diverse sources when cultured in four infection-relevant growth conditions (LB, M9 glucose, sputum, and serum) (65). Interestingly, most of these strains did not require *gltA* for growth in urine (65, 66). However, the current work highlights the risk of targeting GltA exclusively, since *Pa* can swiftly compensate for the loss of GltA activity by increasing PrpC expression (through PrpR inactivation) (**Figure 7**).

Mutations in core metabolic genes are strongly associated with antimicrobial resistance, although our insight the mechanistic basis for this is poorly understood (67–69). Crucially, pathogen lifestyles vary, and this in turn leads to major alterations in the regulatory architecture of primary metabolism. These design variations mean that many of the metabolic innovations that facilitate adaptation to new environments (or to antimicrobial challenge) are pathogen specific.

Can we predict the potential routes of mutation and genetic evolution? Addressing this is a central challenge for evolutionary systems biology, and requires a clear understanding and appreciation of microbial metabolic network diversity. As shown in the

current work, large-scale comparative ‘omics analyses, in combination with reverse genetics, can provide mechanistic insights into the complex evolutionary trajectories of underground metabolism. Indeed, the specific path to de-repression of *prpC* expression in *Pa* (via *prpR* inactivation) that allows the cell to survive in the absence of citrate synthase simply cannot happen in *E. coli* or indeed, in many other human pathogens, due to key differences in metabolic architecture, enzymology, and gene regulation (70). Therefore, the strategic inhibition of organic acid catabolism in *Pa* through inhibition of PrpC and GltA activity may be a potent mechanism to halt the growth of this pathogen during infection in environments where propionate is abundant.

Acknowledgements

This work was funded by grants BB/M019411/1 and BB/R005435/1/FAPESP from the BBSRC. SKD was supported by a Herchel Smith Postdoctoral Fellowship. Elements of this work were supported by an EMBO Short Term Fellowship to SKD (7293-2017). CW acknowledges support by the German Federal Ministry for Education and Research (BMBF) through the grants “BioNylon” (FKZ 03V0757) and “LignoValue” (FKZ 031B0344A) and by the German Research Foundation (DFG) through the grant “ePseudomonas” (WI-1796/4-1) within the Priority Programme “eBiotech” (SPP 2240). We thank the Cambridge Centre for

Proteomics, including Dr Mike Deery, Mrs Renata Feret and Prof Kathryn Lilley for proteomics support.

Competing Interests Statement

The authors declare that they have no competing interests.

Materials and Methods

Growth conditions.

Unless otherwise indicated, *P. aeruginosa* strain PAO1 (71) was routinely grown in lysogeny broth (LB LENNOX) (Oxoid Ltd) at 37°C with good aeration (shaking at 250 rpm). The strains used in this study are listed in **Table S1A**. The overnight pre-cultures were started from separate clonal source colonies on streaked LB agar plates. Strains were cultured in MOPS

(morpholinepropanesulfonic acid) media with the relevant carbon sources (72). Cell growth was monitored as optical density in a spectrophotometer (BioSpectrometer®, Eppendorf) at a wavelength of 600 nm (OD₆₀₀). A previously determined conversion factor of 0.42 g cell dry weight (CDW) per OD₆₀₀ unit was used to calculate biomass specific rates and yields from the obtained OD₆₀₀ values (73).

Transcriptomics (RNA-Seq).

P. aeruginosa strain PAO1 and $\Delta prpC$ were grown in 40 ml MOPS with succinate (30 mM) as the sole carbon source (six flasks per strain) at 37°C with good aeration (shaking at 250 rpm) in baffled flasks (500 ml volume). At OD₆₀₀ 0.2, 500 μ M sodium propionate was spiked into three of the PAO1 cultures and three of the $\Delta prpC$ cultures. An equal volume of H₂O was added to the control PAO1 and $\Delta prpC$ cultures. After 2 hr, an aliquot (5 ml) of culture was removed from each sample. At this stage, the culture OD₆₀₀ was $\cong$ 0.7 (exponential growth). These aliquots were added to an equal volume of RNeasy® RNA stabilization solution. RNA was then isolated using a RNeasy Mini Kit (Qiagen). Ribosomal RNA (rRNA) was subsequently depleted from each RNA sample (5 μ g each) using the bacterial Ribo-Zero rRNA Removal Kit (Illumina). The integrity of the RNA was evaluated using an RNA 6000 Nano LabChip and an Agilent 2100 Bioanalyzer (Agilent Technologies, Germany). Twelve indexed, strand-specific cDNA libraries were prepared, and samples were sequenced on an Illumina HiSeq 2000 with a 51 bp single-end read length (GATC Biotech, Germany). The sequencing data are deposited at ArrayExpress (accession number E-MTAB-10077).

Reads mapping and annotations.

The FASTQ files were mapped to the PAO1 genome obtained from the Pseudomonas Genome Database (PGD) (<http://www.pseudomonas.com/>) using Bowtie v.0.12.8

[38]. The sequence reads were adaptor clipped and quality trimmed with trimmomatic (74) using the default parameters. The Integrative Genomics Viewer was used to visually inspect mapping quality and the absence of *prpC* reads in the $\Delta prpC$ mutant. Read summarization was performed using featureCounts (75). DESeq2 was employed to analyse differentially-expressed genes (76). Annotations of differentially expressed genes were obtained from the reference annotation of the *Pseudomonas* genome available at the PGD website. Genes were considered as significantly induced or repressed when their adjusted-P value was <0.05 (File S3).

Quantitative proteomic analysis.

P. aeruginosa PAO1 cells (OD₆₀₀ = 0.5, 30 ml) were grown at 37°C in 40 ml MOPS with succinate (30 mM) or propionate (40 mM) as the sole carbon source, with good aeration (shaking at 250 rpm) in baffled flasks (500 ml volume). Cultures were grown and analysed in triplicate. The cell pellets were resuspended in 2 ml lysis buffer (100 mM Tris-HCl, 50 mM NaCl, 10% (v/v) glycerol, 1 mM *tris*(2-carboxyethyl)phosphine (TCEP), pH 7.5) containing one cOmplete Mini protease inhibitor cocktail (Roche). Following three rounds of sonication (3 × 10 sec) on ice, supernatants were clarified by sedimentation (21130 × *g*, 15 min, 4°C) in an Eppendorf 5424R centrifuge. Aliquots (100 µg) of each sample were reduced with TCEP, alkylated with iodoacetamide and labelled with Tandem Mass Tags (TMTs). TMT labelling was carried out according to the manufacturer's protocol.

LC-MS/MS.

LC-MS/MS analyses were carried out using a Dionex Ultimate 3000 RSLC nanoUPLC (Thermo Fisher Scientific Inc, Waltham, MA, USA) system in-line with a Lumos Orbitrap mass spectrometer (Thermo Fisher Scientific Inc, Waltham, MA, USA) (27). Separation of peptides

was performed by C18 reverse-phase chromatography at a flow rate of 300 nL/min using a Thermo Scientific reverse-phase nano Easy-spray column (Thermo Scientific PepMap C18, 2 μ m particle size, 100 Å pore size, 75 μ m i.d. x 50 cm length).

Proteomic data analysis.

Proteome Discoverer v2.1 (Thermo Fisher Scientific) and Mascot (Matrix Science) v2.6 were used to process raw data files. The data were aligned with the UniProt *Pseudomonas aeruginosa* (5584 sequences) common repository of adventitious proteins (cRAP) v1.0. The R package, MSnbase (77), was used for processing proteomics data. Protein differential abundance was evaluated using the Limma package (78). Differences in protein abundances were statistically determined using Student's *t*-test with variances moderated by Limma's empirical Bayes method. *P*-values were adjusted for multiple testing by the Benjamini-Hochberg method (79). Proteins were considered as increased or decreased in abundance, when their log₂ fold-change was >1 or <-1, respectively, and their *p*-value was <0.05. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium *via* the PRIDE (55) partner repository with the data set identifier PXD015792.

Genome sequencing.

Genomic DNA was extracted from PAO1 and three evolved Δ *gltA* mutants (EVOL_1-3) using a GeneJET Genomic DNA Purification Kit following 50 generations of growth in MOPS-succinate. Genome sequencing of all four strains was carried out by MicrobesNG (<http://www.microbesng.uk>), and the reads were analysed and displayed using IGV (80).

Construction of in-frame *P. aeruginosa* PAO1 deletion mutants.

Flanking regions 800-1000 bp upstream and downstream of the desired genes were PCR amplified. The upstream and downstream regions were then overlapped and cloned into the suicide vector, pEX19Gm, using Gibson assembly as described previously (81). The resulting deletion plasmid was then introduced into *P. aeruginosa* by electroporation and selected for on LB plates containing 50 µg/ml gentamicin. Deletion mutants were identified via SacB-mediated sucrose counter-selection and confirmed by PCR. Primers used are described in **Table S1B**.

Construction of luciferase reporter strains.

Transcriptional reporter constructs were made by fusing the upstream promoter sequences of the indicated genes with the *luxCDABE* cluster using the primers listed in **Table S1B**. The purified PCR products were digested and directionally ligated into the multiple cloning site of plasmid pUC18T-mini-Tn7T-lux-Gm (82). The mini-Tn7-lux element was introduced into PAO1 (where it integrated into the chromosome) by electroporation along with the helper plasmid pTNS2, as previously described (83). Luciferase and OD₆₀₀ readings were measured using a BMG Labtech FLUOstar Omega microplate reader. Strains were cultured in MOPS media with the indicated carbon sources (100 µL) in 96-well microplates (Greiner bio-one, F-Bottom, Black) covered with gas permeable imaging seals (4titude - 4ti-0516/96). Luciferase expression was assessed during exponential growth. Growth was measured by taking OD₆₀₀ readings simultaneously with the luminescence readings. Luciferase readings were expressed as relative luminometer units (RLU) normalised to OD₆₀₀ in order to control for growth rate differences in the selected carbon sources.

¹³C fluxomics.

Starter cultures were prepared by inoculating LB medium with a loop of freshly plated PAO1. After 6 hr of incubation, 50 µL of cell suspension was transferred to a second culture of MOPS minimal medium containing the desired substrate (see below). Subsequently, exponentially growing cells were used as an inoculum for the main cultures. In the main cultures, PAO1 was grown in 25 mL of minimal medium in baffled shake flasks (250 mL volume) with good aeration (shaking at 200 rpm, 37°C) in an orbital shaker (Aquatron, Infors AG, Switzerland). In these conditions, the oxygen level is maintained above 80% of saturation (73).

For the second and main cultures, PAO1 was grown in MOPS minimal media with 40 mM propionate or 30 mM succinate as the sole carbon source (i.e., 120 mM carbon in each case). For ¹³C flux experiments, naturally labelled propionate and succinate was replaced with separate tracers (three for propionate, two for succinate) to maximise dataset resolution and to accurately determine substrate uptake. Naturally labelled propionate was substituted with [1,3-¹³C₂] sodium propionate (99%), [3-¹³C] sodium propionate (99%) and an equimolar mixture of [U-¹³C₃] sodium propionate (99%) and naturally labelled sodium propionate (Sigma-Aldrich, Poole, Dorset, UK). Naturally labelled succinate was substituted with 99% [1,4-¹³C₂] sodium succinate, 99% [2,3-¹³C₂] sodium succinate or an equimolar molar 1:1 mixture of [U-¹³C₄] sodium succinate (obtained from Cambridge Isotope Laboratories, Inc., Andover, MA, USA) and naturally labelled sodium succinate.

In cultures incubated with ¹³C-tracer, the inoculum (initial OD < 0.02) was always kept below 1% of the final sampled cell concentration to exclude potential interference of non-labelled cells on subsequent calculation of flux (84). Mass isotopomer labelling analysis of

proteinogenic amino acids, mass isotopomer labelling analysis of cell sugar monomers (glucose, ribose and glucosamine), metabolic reaction network and flux calculation were carried out as described in (20).

Quantification of substrates and products.

Propionate and succinate, as well as organic acids (citric acid, α -ketoglutaric acid, gluconic acid, 2-ketogluconic acid, pyruvic acid, succinic acid, lactic acid, formic acid, fumaric acid, and acetic acid) were quantified in filtered culture supernatants (Costar® Spin-X® 0.22 μ m) using isocratic high-performance liquid chromatography (Agilent 1260 Infinity series, s HPX-87H column operating at 65°C and a flow rate of 0.5 mL min⁻¹) equipped with refractive index (RI) and ultraviolet (UV) detectors (210 nm) with 12 - 50 mM H₂SO₄ as an eluent (85). Concentrations were determined from commercial standards which were analysed on the same run. These data were then used to calculate specific uptake and formation rates, and biomass yields for propionate, succinate, and secreted by-products, respectively (File S2).

Calculation of redox cofactor and ATP balances.

Total production of reduced cofactors was determined by summing up all cofactor-forming fluxes taking into account substrate-dependent cofactor specificities (86–88). Anabolic NADPH requirements and anabolically-produced NADH were estimated from the biomass composition (73, 89) and measured specific growth rates. Surplus NADPH was considered to be converted into NADH *via* the activities of a soluble (SthA, PA2991) and a membrane-bound, proton-translocating (PntAB, PA0195-PA0196) pyridine nucleotide transhydrogenases (34).

ATP: The total ATP demand was calculated by summing up (i) the anabolic demand needed for biomass building block synthesis, and (ii) polymerisation estimated from cell composition multiplied with the corresponding specific growth rate on each substrate (20, 73). We also took into account the costs of growth-associated maintenance (GAM) and non-growth-associated maintenance (NGAM) (90) and ATP costs for substrate activation; the full reaction reference network is shown in **File S2**, (91). The ATP synthesized by oxidative phosphorylation *via* the respiratory chain was estimated assuming a P/O ratio of 1.875 for NADH and PQQH₂ (92) and 1.0 for FADH₂ and other quinone (QH₂) carriers (93), respectively. The anabolic ATP requirement was calculated from published biomass composition data for pseudomonads (mainly protein, RNA and lipid synthesis) inclusive of the costs of polymerising the precursors of these components (73, 94). The GAM and NGAM costs for pseudomonads was previously modelled using genome-scale models (90, 95). Here, an ATP surplus represents the amount of ATP available to fulfil remaining cellular ATP-consuming tasks.

Western-blot analysis.

Equal amounts of protein (10 µg) were resolved on a 12% SDS—polyacrylamide gel. The resolved proteins were blotted onto a nitrocellulose membrane, which was blocked with 5% (w/v) skimmed milk powder in TBS buffer. The membranes were probed with rabbit-derived anti-ICD antibodies, anti-PrpC antibodies or anti-PrpB antibodies (polyclonal antibodies raised by BioGenes.De). Following washing to remove excess primary antibody, the membranes were then probed with IRDye® 800CW goat anti-rabbit IgG secondary antibodies (926-32211). Bands were visualized on an Odyssey Infrared Imaging System (LI-COR Biosciences).

Enzymatic assays.

The 2-methylcitrate synthase (2-MCS) activity of PrpC was measured using a method described by Srere *et al* (96) except that propionyl-CoA (PrCoA) was used instead of acetyl-CoA (AcCoA). Briefly, the condensation reaction of oxaloacetate (OAA) and PrCoA facilitated by PrpC generates free coenzyme A (CoA). The free CoA thiol group on the liberated CoA reacts with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) to yield 2-nitro-5-thiobenzoate (TNB²⁻) anions. TNB²⁻ is coloured and its formation can be monitored at 412 nm. The initial rate was calculated from the rate of change of the A₄₁₂ assuming an extinction coefficient for TNB²⁻ of 14,150 M⁻¹ cm⁻¹. The reaction mixtures contained buffer (50 mM HEPES pH 7.5, 0.1 M KCl, and 0.54 M glycerol), substrates (OAA and PrCoA at the indicated concentrations) and 0.15 mM DTNB. Reaction mixtures were equilibrated at 37°C for 5 min before the reaction was initiated by the addition of PrpC (to a final concentration of 240 nM). The reaction was kept in 37°C and the A₄₁₂ was measured in a BioSpectrometer® (Eppendorf). Kinetic parameters were calculated using best-fit nonlinear regression and plotted using GraphPad Prism version 6. The citrate synthase (CS) activity of PrpC was measured using the method above but AcCoA in place of PrCoA. The 2-MCS and CS activity of GltA was measured using PrCoA and AcCoA respectively.

Protein expression.

The PCR-amplified ORFs of *prpC*, *gltA* and *prpR* were cloned into the expression vector pET-19m, which introduces a TEV-cleavable N-terminal hexahistidine tag onto each protein. For purification of the His₆-tagged proteins, the cells were grown in LB medium (1 L) at 37°C with good aeration to A₆₀₀ = 0.5. The temperature was then lowered to 16°C, and isopropyl 1-thio-β-D-galactopyranoside was added to 1 mM final concentration to induce expression

of the cloned genes. The induced cultures were grown for a further 16 h and then harvested by sedimentation (6000 × *g*, 4°C, 15 min). The cell pellet was resuspended in 20 ml of buffer A (50 mM sodium phosphate, 100 mM NaCl, 10% (v/v) glycerol, pH 8.0, containing one dissolved cOmplete™ EDTA-free Protease Inhibitor cocktail tablet (Roche)), and the cells were ruptured by sonication (3 × 10 s, Soniprep 150, maximum power output). The cell lysate was clarified by centrifugation (11,000 × *g*, 4 °C, 30 min), and the supernatant was filtered through a 0.45-μm filter. The filtered lysate was then loaded onto a 5 ml Ni-NTA Superflow column (Qiagen), and the column was washed with buffer A containing 10 mM imidazole. The His₆-tagged proteins were eluted with buffer A containing 250 mM imidazole. His₆-tagged TEV-protease (1 mg) was added to the purified protein solution, and the mixture was dialyzed overnight at 4°C against 2 litres of buffer B (20 mM Tris-HCl, 50 mM NaCl, 5% (v/v) glycerol, pH 7.5). Uncleaved protein and the His₆-TEV protease were removed by batch extraction in a slurry of Ni-NTA resin equilibrated in buffer B. The unbound (cleaved) protein was concentrated to the desired concentration using an Amicon® Ultra-4 Centrifugal Filter (10 kDa NMW cut-off).

Protein crystallization.

PrpC. Crystallization conditions were screened using the sitting drop vapour diffusion technique with approximately 13-15 mg/mL of purified PrpC solution. Optimization conditions were prepared using dragonfly® discovery system (TTP LabTech). Protein drops were generated using an automated nanoliter liquid handler mosquito® HTS (TTP LabTech). PrpC apo- and holo- (OAA-bound) crystals were obtained in a 1:1 ratio of protein and reservoir solution (100-200 mM bis-Tris pH 5.5, 20-30% (w/v) PEG 3350, and 0.1% D-xylose). To obtain the OAA-bound structure of PrpC, the crystallization solution additionally

contained 2.5 mM oxaloacetate. All crystals were grown for 2-11 days at 19°C, and were cryoprotected with 25% (v/v) glycerol and 75% (v/v) reservoir solution prior to mounting in nylon loops (Hampton Research). Mounted crystals were flash frozen in liquid nitrogen prior to data collection.

GltA. Purified GltA at a concentration of 20-25 mg/mL was crystallized by sitting drop vapour diffusion. Crystals were grown for 7 days at 19°C, and were cryoprotected with 25% (v/v) glycerol prior to being mounted and flash frozen for data collection.

X-ray diffraction, structure determination and refinement.

PrpC. Diffraction data was collected on beamline MX-I03 at the Diamond Light Source Synchrotron (DLS, Didcot, UK). The parameters for the data collection were as follows; Omega (Ω) Start: 62.0°, Ω Oscillation: 0.10°, Total Oscillation: 180°, Total Images: 1800, Exposure Time: 0.050 s. Diffraction images were processed using Xia2 DIALS (97). The structure was determined by molecular replacement using Phaser (98) with the atomic coordinates of the PrpC from *Coxiella burnetii* (PDB entry: 3TQG) as the search model. Automated refinement was performed using Refmac5 (99) and PHENIX.refine (100). Manual modelling and refinement were performed in COOT (101). Data collection and refinement statistics are listed in **Table S1D**.

GltA. Data was collected on MX-I03 beamline at the Diamond Light Source Synchrotron (DLS, Didcot, UK). The parameters for the data collection were as follows; Omega (Ω) Start: 0°, Ω Oscillation: 0.20°, Total Oscillation: 240°, Total Images: 1200, Exposure Time: 0.050s. Diffraction images were processed using Xia2 DIALS (102). The structure was determined by molecular replacement using Phaser (98) with the atomic coordinates of the type II citrate synthase from *Vibrio vulnificus* (PDB entry: 4E6Y) as the search model. Automated

refinement was performed using Refmac5 (103) and PHENIX.refine (104). Manual modelling and refinement were performed in COOT (105). Data collection and refinement statistics are listed in **Table S1D**.

Analytical ultracentrifugation.

Analytical ultracentrifugation-sedimentation velocity (AUC-SV) was conducted in the Department of Biochemistry (University of Cambridge) Biophysics Facility. Samples were dialyzed overnight at 4°C against a buffer solution containing 100 mM NaCl and 50 mM Tris-HCl pH 7.5 to remove traces of glycerol. Data were collected using an An60Ti analytical rotor (Beckman Coulter) in a Beckman Optima XL-I ultracentrifuge with absorbance and interference optical detection systems. Protein solution (400 µL volume, concentration approximately 1 mg mL⁻¹) and the reference solution (dialysate) were added to the Epon (epoxy) double-sector centrepieces. All samples were sedimented at 40,000 rpm and 20°C. Absorbance data (A_{280}) were collected in intervals of 2 min and interference scans were taken every 1 min. The viscosity and density of the buffer used in the experiments were estimated with SEDNTERP. Data analysis were conducted using SEDFIT.

Protein thermal stability.

Differential scanning fluorimetry experiments were carried out using a CFX Connect RT-PCR detection system (BioRad) and using Hard-Shell® 96-well PCR plates (BioRad) which are compatible with the excitation and emission wavelength of SYPRO orange. The temperature range was 4-95°C with an increment of 1°C every 45 s. The fluorescence was measured every 15 s. Data was analysed using GraphPad Prism 6.

EMSA analysis.

The region upstream of *prpR* (250 bp, including the 12-nucleotide palindrome) was PCR-amplified. The forward primer contained a 6-FAM (6-carboxyfluorescein) tag (Sigma). EMSA reaction mixtures (25 µL volume) contained buffer (20% (v/v) glycerol, 30 mM Tris-HCl (pH 8.0), 1 mM MnCl₂, 120 mM KCl, 1 mM MgCl₂) supplemented with 5 pM 6-FAM-labeled probe, up to 2 µM recombinant His₆-PrpR, 240 µg/mL bovine serum albumin (BSA), and 15.2 µg/mL poly[d(I-C)]. After incubation at 21°C for 60 min, individual samples were applied to a 6% polyacrylamide gel (Novex) prepared in Tris-borate-EDTA buffer. The samples were electrophoresed in the same buffer system for 45 min at 120 V. The gels were then imaged using an Odyssey imager (Li-Cor Biosciences). In the competition EMSA, unlabelled competitor probes harbouring specific nucleotide substitutions were added in 50-fold molar excess relative to the labelled probes.

LC-MS analysis of propionyl-CoA.

Sampling, analysis and quantification of propionyl-CoA and other CoA esters was carried out as described previously (106). Briefly, cells from 8 mL cultures grown to OD₆₀₀ 2 were pelleted and re-suspended in 200 µL “supercool” ultra-pure water (0°C) and 1 mL quenching-extraction buffer (95% acetonitrile, 25 mM formic acid, -20°C). The mixture was vortexed then kept on ice for 10 min, and finally, centrifuged (3 min, 0°C). The supernatants were transferred into 3 mL of ultra-pure water, then snap-frozen in liquid nitrogen and lyophilized (Alpha 3-4 LSCbasic, Christ, Germany). The freeze-dried samples were diluted in 500 µL pre-cooled resuspension buffer (25 mM ammonium formate, pH 3.0, 2% methanol, 4°C) and immediately analysed by LC-MS (a QTRAP 6500+ (AB Sciex, Darmstadt, Germany) coupled to an HPLC system (Agilent Infinity 1290)). Commercial standards were used for quantification. Final concentrations are given as nmol per gram dry cell weight (DCW).

References

1. Rossi E, La Rosa R, Bartell JA, Marvig RL, Haagenen JAJ, Sommer LM, Molin S, Johansen HK. 2020. *Pseudomonas aeruginosa* adaptation and evolution in patients with cystic fibrosis. *Nature Reviews Microbiology* 2020 19:5 19:331–342.
2. Sonnleitner E, Abdou L, Haas D. 2009. Small RNA as global regulator of carbon catabolite repression in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 106:21866–71.
3. Sun Z, Kang Y, Norris MH, Troyer RM, Son MS, Schweizer HP, Dow SW, Hoang TT. 2014. Blocking Phosphatidylcholine Utilization in *Pseudomonas aeruginosa*, via Mutagenesis of Fatty Acid, Glycerol and Choline Degradation Pathways, Confirms the Importance of This Nutrient Source In Vivo. *PLOS ONE* 9:e103778.
4. Palmer KL, Mashburn LM, Singh PK, Whiteley M. 2005. Cystic fibrosis sputum supports growth and cues key aspects of *Pseudomonas aeruginosa* physiology. *J Bacteriol* 187:5267–5277.
5. Flynn JM, Niccum D, Dunitz JM, Hunter RC. 2016. Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease. *PLOS Pathogens* 12:e1005846.
6. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. 2016. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*. Cell Press <https://doi.org/10.1016/j.cell.2016.05.041>.
7. Dolan SK, Wijaya A, Geddis SM, Spring DR, Silva-Rocha R, Welch M. 2018. Loving the poison: The methylcitrate cycle and bacterial pathogenesis. *Microbiology (United Kingdom)* 164.
8. Muñoz-Elías EJ, Upton AM, Cherian J, McKinney JD. 2006. Role of the methylcitrate cycle in *Mycobacterium tuberculosis* metabolism, intracellular growth, and virulence. *Molecular Microbiology* 60:1109–1122.
9. Catenazzi MCE, Jones H, Wallace I, Clifton J, Chong JPJ, Jackson MA, Macdonald S, Edwards J, Moir JWB. 2014. A large genomic island allows *N. eisseria meningitidis* to utilize propionic acid, with implications for colonization of the human nasopharynx. *Molecular Microbiology* 93:346–355.
10. Ibrahim-Granet O, Dubourdeau M, Latgé JP, Ave P, Huerre M, Brakhage AA, Brock M. 2008. Methylcitrate synthase from *Aspergillus fumigatus* is essential for manifestation of invasive aspergillosis. *Cellular Microbiology* 10:134–148.
11. Rohmer L, Hocquet D, Miller SI. 2011. Are pathogenic bacteria just looking for food? Metabolism and microbial pathogenesis. *Trends in Microbiology* 19:341–348.
12. Feng J, He L, Xiao X, Chen Z, Chen C, Chu J, Lu S, Li X, Mylonakis E, Xi L. 2020. Methylcitrate cycle gene MCD is essential for the virulence of *Talaromyces marneffe*. *Medical Mycology* 58:351–361.
13. Feinbaum RL, Urbach JM, Liberati NT, Djonovic S, Adonizio A, Carvunis A-R, Ausubel FM. 2012. Genome-Wide Identification of *Pseudomonas aeruginosa* Virulence-Related Genes Using a *Caenorhabditis elegans* Infection Model. *PLoS Pathogens* 8:e1002813.

- 880 14. Horswili AR, Escalante-semerena JC, Drive L. 1999. The prpE gene of Salmonella typhimurium
881 LT2 encodes propionyl-CoA synthetase. Microbiology (N Y) 145:1381–1388.
- 882 15. Brock M, Darley D, Textor S, Buckel W. 2001. 2-Methylisocitrate lyases from the bacterium
883 Escherichia coli and the filamentous fungus Aspergillus nidulans. European Journal of
884 Biochemistry 268:3577–3586.
- 885 16. Suvorova IA, Ravcheev DA, Gelfand MS. 2012. Regulation and evolution of malonate and
886 propionate catabolism in proteobacteria. J Bacteriol 194:3234–40.
- 887 17. D'Ari R, Casadesús J. 1998. Underground metabolism. BioEssays 20:181–186.
- 888 18. Liebermeister W, Noor E, Flamholz A, Davidi D, Bernhardt J, Milo R. 2014. Visual account of
889 protein investment in cellular functions. Proc Natl Acad Sci U S A 111:8488–93.
- 890 19. Bernhardt J, Funke S, Hecker M, Siebourg J. 2009. Visualizing gene expression data via
891 voronoi treemaps. 6th International Symposium on Voronoi Diagrams in Science and
892 Engineering, ISVD 2009 233–241.
- 893 20. Kohlstedt M, Wittmann C. 2019. GC-MS-based ¹³C metabolic flux analysis resolves the
894 parallel and cyclic glucose metabolism of Pseudomonas putida KT2440 and Pseudomonas
895 aeruginosa PAO1. Metabolic Engineering 54:35–53.
- 896 21. Lai H, Kraszewski JL, Purwantini E, Mukhopadhyay B. 2006. Identification of pyruvate
897 carboxylase genes in Pseudomonas aeruginosa PAO1 and development of a P. aeruginosa-
898 based overexpression system for α4- and αβ4-type pyruvate carboxylases. Applied and
899 Environmental Microbiology 72:7785–7792.
- 900 22. Kukavica-Ibrulj I, Sanschagrin F, Peterson A, Whiteley M, Boyle B, MacKay J, Levesque RC.
901 2008. Functional genomics of PycR, a LysR family transcriptional regulator essential for
902 maintenance of Pseudomonas aeruginosa in the rat lung. Microbiology (Reading) 154:2106–
903 2118.
- 904 23. Abdelhamid Y, Brear P, Greenhalgh J, Chee X, Rahman T, Welch M. 2019. Evolutionary
905 plasticity in the allosteric regulator-binding site of pyruvate kinase isoform PykA from
906 Pseudomonas aeruginosa. J Biol Chem 294:15505–15516.
- 907 24. Medina V, Pontarollo R, Glaeske D, Tabel H, Goldie H. 1990. Sequence of the pckA gene of
908 Escherichia coli K-12: relevance to genetic and allosteric regulation and homology of E. coli
909 phosphoenolpyruvate carboxykinase with the enzymes from Trypanosoma brucei and
910 Saccharomyces cerevisiae. J Bacteriol 172:7151–7156.
- 911 25. Sauer U, Eikmanns BJ. 2005. The PEP-pyruvate-oxaloacetate node as the switch point for
912 carbon flux distribution in bacteria. FEMS Microbiol Rev 29:765–794.
- 913 26. Crousilles A, Dolan SK, Brear P, Chirgadze DY, Welch M. 2018. Gluconeogenic precursor
914 availability regulates flux through the glyoxylate shunt in Pseudomonas aeruginosa. J Biol
915 Chem 293:14260–14269.
- 916 27. Dolan SK, Kohlstedt M, Trigg S, Vallejo Ramirez P, Kaminski CF, Wittmann C, Welch M. 2020.
917 Contextual Flexibility in Pseudomonas aeruginosa Central Carbon Metabolism during Growth
918 in Single Carbon Sources. mBio 11.

- 919 28. Kell DB, Peck MW, Rodger G, Morris JG. 1981. On the permeability to weak acids and bases of
920 the cytoplasmic membrane of *Clostridium pasteurianum*. *Biochemical and Biophysical*
921 *Research Communications* 99:81–88.
- 922 29. Baronofsky JJ, Schreurs WJA, Kashket ER. 1984. Uncoupling by Acetic Acid Limits Growth of
923 and Acetogenesis by *Clostridium thermoaceticum*. *Applied and Environmental Microbiology*
924 48:1134–1139.
- 925 30. Jacob K, Rasmussen A, Tyler P, Servos MM, Sylla M, Prado C, Daniele E, Sharp JS, Purdy AE.
926 2017. Regulation of acetyl-CoA synthetase transcription by the CrbS/R two-component
927 system is conserved in genetically diverse environmental pathogens. *PLoS One* 12:e0177825.
- 928 31. Gimenez R, Nuñez MF, Badia J, Aguilar J, Baldoma L. 2003. The Gene *yjcG*, Cotranscribed with
929 the Gene *acs*, Encodes an Acetate Permease in *Escherichia coli*. *Journal of Bacteriology*
930 185:6448.
- 931 32. Lundgren BR, Villegas-Peñaranda LR, Harris JR, Mottern AM, Dunn DM, Boddy CN, Nomura
932 CT. 2014. Genetic analysis of the assimilation of C5-Dicarboxylic acids in *pseudomonas*
933 *aeruginosa* PAO1. *Journal of Bacteriology* 196:2543–2551.
- 934 33. Valentini M, Storelli N, Lapouge K. 2011. Identification of C 4-dicarboxylate transport systems
935 in *Pseudomonas aeruginosa* PAO1. *Journal of Bacteriology* 193:4307–4316.
- 936 34. Nikel PI, Pérez-Pantoja D, de Lorenzo V. 2016. Pyridine nucleotide transhydrogenases enable
937 redox balance of *Pseudomonas putida* during biodegradation of aromatic compounds.
938 *Environmental Microbiology* 18:3565–3582.
- 939 35. Massey LK, Sokatch JR, Conrad RS. 1976. Branched chain amino acid catabolism in bacteria.
940 *Bacteriological Reviews*. American Society for Microbiology (ASM)
941 <https://doi.org/10.1128/mmbr.40.1.42-54.1976>.
- 942 36. Steeles MI, Lorenz D, Hatter K, Parkt A, Sokatchs JR. 1992. Characterization of the *mmsAB*
943 Operon of *Pseudomonas aeruginosa* P A 0 Encoding Methylmalonate-semialdehyde
944 Dehydrogenase and 3-Hydroxyisobutyrate Dehydrogenase*.
- 945 37. Cherrington CA, Hinton M, Mead GC, Chopra I. 1991. Organic acids: chemistry, antibacterial
946 activity and practical applications. *Adv Microb Physiol* 32:87–108.
- 947 38. Horswill AR, Dudding AR, Escalante-Semerena JC. 2001. Studies of Propionate Toxicity in
948 *Salmonella enterica* Identify 2-Methylcitrate as a Potent Inhibitor of Cell Growth. *Journal of*
949 *Biological Chemistry* 276:19094–19101.
- 950 39. Brock M, Buckel W. 2004. On the mechanism of action of the antifungal agent propionate.
951 *European Journal of Biochemistry* 271:3227–3241.
- 952 40. Simanshu DK, Satheshkumar PS, Savithri HS, Murthy MRN. 2003. Crystal structure of
953 *Salmonella typhimurium* 2-methylisocitrate lyase (PrpB) and its complex with pyruvate and
954 Mg²⁺. *Biochemical and Biophysical Research Communications* 311:193–201.
- 955 41. Reddick JJ, Sirkisoon S, Dahal RA, Hardesty G, Hage NE, Booth WT, Quattlebaum AL, Mills SN,
956 Meadows VG, Adams SLH, Doyle JS, Kiel BE. 2017. First Biochemical Characterization of a
957 Methylcitric Acid Cycle from *Bacillus subtilis* Strain 168. *Biochemistry* 56:5698–5711.

- 958 42. Gerike U, Hough DW, Russell NJ, Dyall-Smith ML, Danson MJ. 1998. Citrate synthase and 2-
959 methylcitrate synthase: structural, functional and evolutionary relationships. *Microbiology (N*
960 *Y)* 144:929–935.
- 961 43. Horswill AR, Escalante-semerena JC. 1999. Salmonella typhimurium LT2 Catabolizes
962 Propionate via the 2-Methylcitric Acid Cycle Salmonella typhimurium LT2 Catabolizes
963 Propionate via the 2-Methylcitric Acid Cycle 181:5615–5623.
- 964 44. Maurus R, Nguyen NT, Stokell DJ, Ayed A, Hultin PG, Duckworth HW, Brayer GD. 2003.
965 Insights into the evolution of allosteric properties. The NADH binding site of hexameric type II
966 citrate synthases. *Biochemistry* 42:5555–5565.
- 967 45. Chittori S, Savithri HS, Murthy MRN. 2011. Crystal structure of Salmonella typhimurium 2-
968 methylcitrate synthase: Insights on domain movement and substrate specificity. *Journal of*
969 *Structural Biology* 174:58–68.
- 970 46. Rocco CJ, Escalante-Semerena JC. 2010. In Salmonella enterica, 2-methylcitrate blocks
971 gluconeogenesis. *J Bacteriol* 192:771–8.
- 972 47. Bernhard SA, MacQuarrie RA. 1973. Half-site reactivity and the “induced-fit” hypothesis.
973 *Journal of Molecular Biology* 74:73–78.
- 974 48. Donald LJ, Molgat GF, Duckworth HW. 1989. Cloning, sequencing, and expression of the gene
975 for NADH-sensitive citrate synthase of Pseudomonas aeruginosa. *Journal of Bacteriology*
976 171:5542–5550.
- 977 49. Wiegand G, Remington S, Deisenhofer J, Huber R. 1984. Crystal structure analysis and
978 molecular model of a complex of citrate synthase with oxaloacetate and S-acetyl-
979 coenzyme A. *J Mol Biol* 174:205–219.
- 980 50. Remington S, Wiegand G, Huber R. 1982. Crystallographic refinement and atomic models of
981 two different forms of citrate synthase at 2.7 and 1.7 Å resolution. *Journal of Molecular*
982 *Biology* 158:111–152.
- 983 51. Serafini A, Tan L, Horswell S, Howell S, Greenwood DJ, Hunt DM, Phan MD, Schembri M,
984 Monteleone M, Montague CR, Britton W, Garza-Garcia A, Snijders AP, VanderVen B, Gutierrez
985 MG, West NP, de Carvalho LPS. 2019. Mycobacterium tuberculosis requires glyoxylate shunt
986 and reverse methylcitrate cycle for lactate and pyruvate metabolism. *Molecular Microbiology*
987 112:1284–1307.
- 988 52. Behrends V, Bell TJ, Liebeke M, Cordes-Blauert A, Ashraf SN, Nair C, Zlosnik JEA, Williams HD,
989 Bundy JG. 2013. Metabolite profiling to characterize disease-related bacteria: Gluconate
990 excretion by pseudomonas aeruginosa mutants and clinical isolates from cystic fibrosis
991 patients. *Journal of Biological Chemistry* 288:15098–15109.
- 992 53. Kretzschmar U, Khodaverdi V, Adrian L. 2010. Transcriptional regulation of the acetyl-CoA
993 synthetase gene acsA in Pseudomonas aeruginosa. *Arch Microbiol* 192:685–690.
- 994 54. Badal D, Jayarani AV, Kollaran MA, Prakash D, P M, Singh V. 2021. Foraging Signals Promote
995 Swarming in Starving Pseudomonas aeruginosa. *mBio* [https://doi.org/10.1128/MBIO.02033-](https://doi.org/10.1128/MBIO.02033-21)
996 [21](https://doi.org/10.1128/MBIO.02033-21).
- 997 55. Rojo F. 2010. Carbon catabolite repression in Pseudomonas: optimizing metabolic versatility
998 and interactions with the environment. *FEMS Microbiology Reviews* 34:658–684.

- 999 56. Sonleitner E, Valentini M, Wenner N, Haichar F el Z, Haas D, Lapouge K. 2012. Novel Targets
1000 of the CbrAB/Crc Carbon Catabolite Control System Revealed by Transcript Abundance in
1001 *Pseudomonas aeruginosa*. PLoS ONE 7:e44637.
- 1002 57. Lord DM, Uzgoren Baran A, Soo VWC, Wood TK, Peti W, Page R. 2014. McbR/YncC:
1003 Implications for the mechanism of ligand and DNA binding by a bacterial gntR transcriptional
1004 regulator involved in biofilm formation. Biochemistry 53:7223–7231.
- 1005 58. Plassmeier J, Persicke M, Pühler A, Sterthoff C, Rückert C, Kalinowski J. 2012. Molecular
1006 characterization of PrpR, the transcriptional activator of propionate catabolism in
1007 *Corynebacterium glutamicum*. Journal of Biotechnology 159:1–11.
- 1008 59. Lee SK, Keasling JD. 2005. A Propionate-Inducible Expression System for Enteric Bacteria
1009 Downloaded from. APPLIED AND ENVIRONMENTAL MICROBIOLOGY 71:6856–6862.
- 1010 60. Tang S, Hicks ND, Cheng YS, Silva A, Fortune SM, Sacchettini JC. 2019. Structural and
1011 functional insight into the Mycobacterium tuberculosis protein PrpR reveals a novel type of
1012 transcription factor. Nucleic Acids Research 47:9934–9949.
- 1013 61. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood
1014 G, Laydon A, Židek A, Green T, Tunyasuvunakool K, Petersen S, Jumper J, Clancy E, Green R,
1015 Vora A, Lutfi M, Figurnov M, Cowie A, Hobbs N, Kohli P, Kleywegt G, Birney E, Hassabis D,
1016 Velankar S. 2022. AlphaFold Protein Structure Database: massively expanding the structural
1017 coverage of protein-sequence space with high-accuracy models. Nucleic Acids Research
1018 50:D439–D444.
- 1019 62. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates
1020 R, Židek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-
1021 Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M,
1022 Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW,
1023 Kavukcuoglu K, Kohli P, Hassabis D. 2021. Highly accurate protein structure prediction with
1024 AlphaFold. Nature 2021 596:7873 596:583–589.
- 1025 63. Tummler K, Zimmermann M, Schubert OT, Aebersold R, Kühn C, Sauer U, Klipp E. 2018. Two
1026 parallel pathways implement robust propionate catabolism and detoxification in
1027 mycobacteria. bioRxiv 258947.
- 1028 64. VanderVen BC, Fahey RJ, Lee W, Liu Y, Abramovitch RB, Memmott C, Crowe AM, Eltis LD,
1029 Perola E, Deininger DD, Wang T, Locher CP, Russell DG. 2015. Novel Inhibitors of Cholesterol
1030 Degradation in Mycobacterium tuberculosis Reveal How the Bacterium’s Metabolism Is
1031 Constrained by the Intracellular Environment. PLOS Pathogens 11:e1004679.
- 1032 65. Poulsen BE, Yang R, Clatworthy AE, White T, Osmulski SJ, Li L, Penaranda C, Lander ES,
1033 Shores N, Hung DT. 2019. Defining the core essential genome of *Pseudomonas aeruginosa*.
1034 Proc Natl Acad Sci U S A 116:10072–10080.
- 1035 66. Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M. 2015. Essential genome of
1036 *Pseudomonas aeruginosa* in cystic fibrosis sputum. Proc Natl Acad Sci U S A 112:4110–5.
- 1037 67. Lopatkin AJ, Bening SC, Manson AL, Stokes JM, Kohanski MA, Badran AH, Earl AM, Cheney NJ,
1038 Yang JH, Collins JJ. 2021. Clinically relevant mutations in core metabolic genes confer
1039 antibiotic resistance. Science 371.

1040 68. Gil-Gil T, Corona F, Martínez JL, Bernardini A. 2020. The Inactivation of Enzymes Belonging to
1041 the Central Carbon Metabolism Is a Novel Mechanism of Developing Antibiotic Resistance.
1042 mSystems 5.

1043 69. Murima P, McKinney JD, Pethe K. 2014. Targeting bacterial central metabolism for drug
1044 development. Chem Biol 21:1423–1432.

1045 70. Guzmán GI, Utrilla J, Nurk S, Brunk E, Monk JM, Ebrahim A, Palsson BO, Feist AM. 2015.
1046 Model-driven discovery of underground metabolic functions in Escherichia coli. Proc Natl
1047 Acad Sci U S A 112:929–934.

1048 71. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrenner P, Hickey MJ, Brinkman FSL, Hufnagle
1049 WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrook-Wadman S, Yuan Y,
1050 Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK-S, Wu Z,
1051 Paulsen IT, Reizer J, Saier MH, Hancock REW, Lory S, Olson M V. 2000. Complete genome
1052 sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959–
1053 964.

1054 72. LaBauve AE, Wargo MJ. 2012. Growth and laboratory maintenance of Pseudomonas
1055 aeruginosa. Curr Protoc Microbiol Chapter 6:Unit 6E.1.

1056 73. Berger A, Dohnt K, Tielen P, Jahn D, Becker J, Wittmann C. 2014. Robustness and Plasticity of
1057 Metabolic Pathway Flux among Uropathogenic Isolates of Pseudomonas aeruginosa. PLoS
1058 ONE 9:e88368.

1059 74. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence
1060 data. Bioinformatics 30:2114–2120.

1061 75. Liao Y, Smyth GK, Shi W. 2019. The R package Rsubread is easier, faster, cheaper and better
1062 for alignment and quantification of RNA sequencing reads. Nucleic Acids Research 47.

1063 76. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for
1064 RNA-seq data with DESeq2. Genome Biology 15:550.

1065 77. Gatto L, Lilley KS. 2012. MSnbase-an R/Bioconductor package for isobaric tagged mass
1066 spectrometry data visualization, processing and quantitation. Bioinformatics 28:288–289.

1067 78. Smyth GK. 2005. limma: Linear Models for Microarray Data, p. 397–420. In Bioinformatics and
1068 Computational Biology Solutions Using R and Bioconductor. Springer-Verlag, New York.

1069 79. Benjamini Y, Hochberg Y. 1995. Controlling the False Discovery Rate: A Practical and Powerful
1070 Approach to Multiple Testing. Journal of the Royal Statistical Society Series B
1071 (Methodological). WileyRoyal Statistical Society <https://doi.org/10.2307/2346101>.

1072 80. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. 2011.
1073 Integrative genomics viewer. Nature Biotechnology 29:1 29:24–26.

1074 81. Huang W, Wilks A. 2017. A rapid seamless method for gene knockout in Pseudomonas
1075 aeruginosa. BMC Microbiol 17:199.

1076 82. Choi K-H, Schweizer HP. 2006. mini-Tn7 insertion in bacteria with single attTn7 sites: example
1077 Pseudomonas aeruginosa. Nature Protocols 1:153–161.

- 1078 83. Heath Damron F, McKenney ES, Barbier M, Liechti GW, Goldberg JB. 2013. Construction of
1079 Mobilizable Mini-Tn7 Vectors for Bioluminescent Detection and Single Copy Promoter lux
1080 Reporter Analysis in Gram-Negative Bacteria. CAMBRIDGE UNIVERSITY LIBRARY
1081 <https://doi.org/10.1128/AEM.00640-13>.
- 1082 84. Wittmann C. 2007. Fluxome analysis using GC-MS. Microb Cell Fact 6:6.
- 1083 85. Kind S, Becker J, Wittmann C. 2013. Increased lysine production by flux coupling of the
1084 tricarboxylic acid cycle and the lysine biosynthetic pathway—Metabolic engineering of the
1085 availability of succinyl-CoA in *Corynebacterium glutamicum*. Metabolic Engineering 15:184–
1086 195.
- 1087 86. Nikel PI, Chavarr??a M, Fuhrer T, Sauer U, De Lorenzo V. 2015. *Pseudomonas putida* KT2440
1088 strain metabolizes glucose through a cycle formed by enzymes of the Entner-Doudoroff,
1089 embden-meyerhof-parnas, and pentose phosphate pathways. Journal of Biological Chemistry
1090 290:25920–25932.
- 1091 87. Rivers DB, Blevins WT. 1987. Multiple Enzyme Forms of Glyceraldehyde-3-phosphate
1092 Dehydrogenase in *Pseudomonas aeruginosa* PAO. Microbiology (N Y) 133:3159–3164.
- 1093 88. Görsch H, Jeoung J-H, Rückert A, Kretzschmar U. 2002. Malate:quinone oxidoreductase is
1094 essential for growth on ethanol or acetate in *Pseudomonas aeruginosa*. Microbiology (N Y)
1095 148:3839–3847.
- 1096 89. Bartell JA, Blazier AS, Yen P, Thøgersen JC, Jelsbak L, Goldberg JB, Papin JA. 2017.
1097 Reconstruction of the metabolic network of *Pseudomonas aeruginosa* to interrogate
1098 virulence factor synthesis. Nature Communications 8:14631.
- 1099 90. Bartell JA, Blazier AS, Yen P, Thøgersen JC, Jelsbak L, Goldberg JB, Papin JA. 2017.
1100 Reconstruction of the metabolic network of *Pseudomonas aeruginosa* to interrogate
1101 virulence factor synthesis. Nature Communications 8:14631.
- 1102 91. Kretzschmar U, Schobert M, Görsch H. 2001. The *Pseudomonas aeruginosa* *acsA* gene,
1103 encoding an acetyl-CoA synthetase, is essential for growth on ethanol. Microbiology (N Y)
1104 147:2671–2677.
- 1105 92. Hardy GPMA, Joost Teixeira de Mattos M, Neijssel OM. 1993. Energy conservation by
1106 pyrroloquinoline quinol-linked xylose oxidation in *Pseudomonas putida* NCTC 10936 during
1107 carbon-limited growth in chemostat culture. FEMS Microbiology Letters 107:107–110.
- 1108 93. Yuan Q, Huang T, Li P, Hao T, Li F, Ma H, Wang Z, Zhao X, Chen T, Goryanin I. 2017. Pathway-
1109 Consensus Approach to Metabolic Network Reconstruction for *Pseudomonas putida* KT2440
1110 by Systematic Comparison of Published Models. PLOS ONE 12:e0169437.
- 1111 94. van Duuren JB, Puchałka J, Mars AE, Bücker R, Eggink G, Wittmann C, dos Santos VAM. 2013.
1112 Reconciling in vivo and in silico key biological parameters of *Pseudomonas putida*KT2440
1113 during growth on glucose under carbon-limited condition. BMC Biotechnology 13:93.
- 1114 95. van Duuren JB, Puchałka J, Mars AE, Bücker R, Eggink G, Wittmann C, dos Santos VAM. 2013.
1115 Reconciling in vivo and in silico key biological parameters of *Pseudomonas putida*KT2440
1116 during growth on glucose under carbon-limited condition. BMC Biotechnology 13:93.
- 1117 96. Srere PA, Brazil H, Gonen L. 1963. The Citrate Condensing Enzyme of Pigeon Breast Muscle
1118 and Moth Flight Muscle. ACTA Chemica Scandinavica.

- 1119 97. Winter G. 2010. Xia2: An expert system for macromolecular crystallography data reduction.
1120 Journal of Applied Crystallography 43:186–190.
- 1121 98. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser
1122 crystallographic software. Journal of Applied Crystallography 40:658–674.
- 1123 99. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F,
1124 Vagin AA. 2011. REFMAC5 for the refinement of macromolecular crystal structures. Acta
1125 Crystallographica Section D: Biological Crystallography 67:355–367.
- 1126 100. Moriarty NW, Headd JJ, Grosse-Kunstleve RW, Afonine P V., Zwart PH, Urzhumtsev A,
1127 Terwilliger TC, Echols N, Adams PD, Mustyakimov M. 2012. Towards automated
1128 crystallographic structure refinement with phenix.refine . Acta Crystallographica Section D
1129 Biological Crystallography 68:352–367.
- 1130 101. Emsley P, Cowtan K. 2004. Coot: Model-building tools for molecular graphics. Acta
1131 Crystallographica Section D: Biological Crystallography 60:2126–2132.
- 1132 102. Winter G. 2010. Xia2: An expert system for macromolecular crystallography data reduction.
1133 Journal of Applied Crystallography 43:186–190.
- 1134 103. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F,
1135 Vagin AA. 2011. REFMAC5 for the refinement of macromolecular crystal structures. Acta
1136 Crystallographica Section D: Biological Crystallography 67:355–367.
- 1137 104. Moriarty NW, Headd JJ, Grosse-Kunstleve RW, Afonine P V., Zwart PH, Urzhumtsev A,
1138 Terwilliger TC, Echols N, Adams PD, Mustyakimov M. 2012. Towards automated
1139 crystallographic structure refinement with phenix.refine . Acta Crystallographica Section D
1140 Biological Crystallography 68:352–367.
- 1141 105. Emsley P, Cowtan K. 2004. Coot: Model-building tools for molecular graphics. Acta
1142 Crystallographica Section D: Biological Crystallography 60:2126–2132.
- 1143 106. Gläser L, Kuhl M, Jovanovic S, Fritz M, Vögeli B, Erb TJ, Becker J, Wittmann C. 2020. A
1144 common approach for absolute quantification of short chain CoA thioesters in prokaryotic
1145 and eukaryotic microbes. Microbial Cell Factories 2020 19:1 19:1–13.

1146

1147

1148

1149

1150 **Figure Legends**

1151 **Figure 1; Proteomic analysis of Pa grown on Succinate and Propionate**

1152 **A**; Schematic depicting the Pa 2-methylcitrate cycle (2MCC) in Pa central carbon
 1153 metabolism. The Pa central metabolic network shown here consists of six main blocks,
 1154 designated with different colours: (i) the Embden-Meyerhoff-Parnas pathway (EMP,
 1155 orange); (ii) the pentose phosphate pathway (PPP, green); (iii) the Entner-Doudoroff
 1156 pathway (EDP, purple); (iv) the tricarboxylic acid cycle (TCA, blue) and glyoxylate shunt (red);
 1157 (v) anaplerotic and gluconeogenic reactions (yellow), and (vi) the 2MCC (pink). The 2MCC
 1158 operon arrangement (inset – grey underline) consists of genes which encode; a
 1159 transcriptional regulator (designated here as *prpR*) which is thought to encode a ligand-
 1160 responsive repressor, a methylcitrate synthase (*prpC*) which condenses propionyl-CoA
 1161 (PrCoA) with oxaloacetate (OAA) to form 2-methylcitrate (2-MC), a 2-methylcitrate
 1162 dehydratase/hydratase (*prpD*) which dehydrates 2-MC to yield 2-methylnaconitate (2-MCA),
 1163 a 2-methylcitrate dehydratase (*acnD*) and 2-methylnaconitate *cis-trans* isomerase (*prpF*)
 1164 which provide an alternative route for the generation of 2-MCA from 2-MC, and a 2-
 1165 methylisocitrate lyase (*prpB*), which cleaves 2-methylisocitrate (2-MIC) to yield pyruvate
 1166 (PYR) and succinate (SUC). Note that the 2-MCA generated in the PrpD or AcnD/PrpF
 1167 reactions is rehydrated by an unlinked aconitase (likely AcnB in Pa) to yield the PrpB
 1168 substrate, 2-MIC. Also, the enzyme responsible for the initial activation of propionate to
 1169 yield PrCoA has not yet been identified for Pa, although in other organisms this function is
 1170 carried out by a dedicated propionyl-CoA synthase (PrpE), or by acetyl-CoA synthase (AcsA),
 1171 or by a combination of phosphotransacetylase (Pta) and acetate kinase (AckA) activities.
 1172 Other abbreviations; AcCoA, acetyl-coenzyme A; CIT, citrate; ICIT, isocitrate; AKG, α -
 1173 ketoglutarate; FUM, fumarate; MAL, malate; KDPG, 2-keto-3-deoxy-6-phosphogluconate;
 1174 G3P, glyceraldehyde 3-phosphate; FBP, fructose 1,6-bisphosphate; F6P, fructose 6-
 1175 phosphate; G6P, glucose 6-phosphate; 6PG, 6-phosphogluconate; Ri5P, ribulose 5-

phosphate; R5P, ribose 5-phosphate; X5P, xylulose 5-phosphate; S7P, sedoheptulose 7-phosphate; E4P, erythrose 4-phosphate; PEP, phosphoenolpyruvate.

B; Illustration of the statistically significant proteomic changes (p -value ≤ 0.05 , fold change ≥ 1 or ≤ -1) during growth on propionate or succinate, as represented by Voronoi tessellations. Pathway assignment was performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) dataset. Proteome alterations which could not be assigned to a specific pathway (uncharacterised/hypothetical proteins) are shown as 'Not Mapped'. The specific protein identities for the protein clusters that were up-regulated during growth on propionate are shown in **Figure S1A** and statistical analyses of these data are illustrated in **Figures S1B-D**. The complete proteomics dataset is presented in **File S1**.

Figure 2; *In vivo* carbon flux distributions in central metabolism of Pa PAO1 during growth on succinate (A) or propionate (B) as sole carbon sources. Flux is expressed as a molar percentage of the average uptake rate for succinate ($23.5 \text{ mmol g}^{-1} \text{ h}^{-1}$) or propionate $28.1 \text{ mmol g}^{-1} \text{ h}^{-1}$), calculated from the individual rates in **File S2**. Anabolic pathways from 11 precursors to biomass are indicated by the filled blue triangles. The flux distributions with bidirectional resolution (i.e., net and exchange fluxes), including the drain from metabolic intermediates to biomass and confidence intervals of the flux estimates, are provided in **File S2**. The errors given for each flux reflect the corresponding 90% confidence intervals. The full flux datasets are presented in *Supporting Information File S2*. Colours qualitatively indicate fluxomic correlation with changes on the protein level during growth on propionate compared with growth on succinate (light green or red $\rightarrow$ significant up- or down-regulation (respectively); dark green or red $\rightarrow$ less significant up- or down-regulation).

1199

Figure 3; The Pa ORF (*prpC*) encoding 2-methylcitrate synthase is essential for growth on propionate. A; Wild-type Pa (PAO1), and the $\Delta acsA$, $\Delta aceA$ and $\Delta prpC$ mutants all grow comparably on MOPS agar containing glucose or succinate as a sole carbon source. $\Delta acsA$ has a growth defect during growth on MOPS-acetate and MOPS-propionate. $\Delta prpC$ cannot grow on MOPS propionate. The plates were photographed after 24 h incubation. **B;** Wild-type PAO1 and the $\Delta acsA$, $\Delta aceA$ and $\Delta prpC$ mutants were cultured on LB agar containing an increasing concentration of propionate (0, 5, 10, 20 mM, as indicated). The $\Delta prpC$ displays a pronounced growth defect in the presence of propionate concentrations > 10 mM. The plates were photographed after 24 h incubation. **C;** Intracellular propionyl-CoA concentration in wild-type Pa (PAO1) and in the $\Delta prpC$ mutant following 3h exposure to propionate (5 mM). Unpaired *t*-test with Welch's correction $p = 0.0026$. The experiment was performed using biological triplicates. **D;** Illustration of the interwoven reactions for propionate and acetate activation in Pa, feeding into the 2-methylcitrate cycle and TCA cycle, respectively. Following uptake, acetate and propionate are activated by AcsA. The resulting propionyl-CoA (PrCoA) is condensed with oxaloacetate (OAA) in a PrpC-catalyzed reaction to form 2-methylcitrate (2-MC), whereas the acetyl-CoA (AcCoA) is condensed with oxaloacetate in a GltA-catalyzed reaction to form citrate (CIT). **E;** Growth of the Pa glyoxylate shunt mutants $\Delta aceA$ and $\Delta glcB$ is blocked on MOPS agar plates containing a combination of high acetate concentration (40 mM) and low propionate concentration (5 mM) as the carbon source. However, this growth inhibition is partially overcome by increasing the propionate concentration to 20 mM (left to right in the figure). The plates were photographed after 48 h growth. The data are representative of two independent experiments, each performed in triplicate.

1223

1224 **Figure 4; Biochemical and structural analysis of PrpC and GltA from Pa.**

1225 **A.** A $\Delta gltA$ mutant exhibits a growth defect when cultured on LB-agar, whereas a $\Delta prpC$
1226 mutant displays a wild-type colony morphotype. The plates were photographed after 48 h.
1227 The data are representative of two independent experiments, each performed in triplicate.

1228 **B.** Purified PrpC_{Pa} exhibits both citrate synthase activity (with acetyl-CoA as a substrate) and
1229 2-methylcitrate synthase activity (with propionyl-CoA as a substrate). The concentration of
1230 OAA in each reaction was fixed at 0.5 mM. The data are representative of two independent
1231 experiments, each performed in triplicate.

1232 **C.** Purified GltA_{Pa} is a citrate synthase with no detectable 2-methylcitrate synthase activity.
1233 The concentration of OAA was fixed at 0.5 mM. The data are representative of two
1234 independent experiments, each performed in triplicate.

1235 **D.** The x-ray crystal structure of PrpC_{Pa} (PDB: 6S6F). PrpC_{Pa} is a homodimer. In the ribbon
1236 diagram shown, the protomers are coloured blue and grey.

1237 **E.** Cartoon representation of the GltA_{Pa} hexamer in the asymmetric unit (left) and, for
1238 comparison with PrpC_{Pa}, the extracted GltA_{Pa} dimers (middle and right).

1239 **F.** Superposition of the PrpC_{Pa} and GltA_{Pa} structures. PrpC_{Pa} and GltA_{Pa} share similar core α -
1240 helical folds (shown in grey to highlight similarities). However, GltA_{Pa} has an additional
1241 antiparallel β -sheet at its N-terminus (coloured in red to showcase differences).

1242

1243 **Figure 5; Structural analysis of oxaloacetate-bound PrpC_{Pa}.**

A; Crystal structure of oxaloacetate-bound PrpC_{Pa} represented in cartoon (PDB: 6S87). One protomer is coloured blue and the other orange. A 90° rotation about the X-axis is shown (right). Oxaloacetate is shown as green and red spheres.

B; Oxaloacetate binding site from *P. aeruginosa* PrpC chain D. Water molecules are shown in cyan spheres. Chain D and chain C residues are shown in orange and cyan, respectively. The electron density map ($2F_o - F_c$) in white is contoured at 1.5σ .

C; Superposition of the PrpC_{Pa} (white), GltA_{Pa} (pink) and *A. fumigatus* PrpC (5UQR) (green) oxaloacetate binding site. Oxaloacetate is shown in orange spheres. Most of the amino acid residues forming this site are conserved, except R307 (GltA_{Pa} numbering).

D; The left-hand panel shows the open (red) apo-conformation of PrpC_{Pa}, the middle panel shows the partially closed (blue) holo-conformation of PrpC_{Pa}, and the right hand panel shows a superposition of both conformations of PrpC_{Pa}. Note the structural rearrangement in the oxaloacetate-bound PrpC_{Pa} protomer (indicated by the red arrow).

Figure 6; RNA-seq analysis uncovers that propionate exposure induces expression of the *prp* operon and of the genes associated with branched chain amino acid catabolism in Pa.

A; Schematic of the experimental design. At OD 0.2, 500 μ M sodium propionate was spiked into (triplicate) cultures of PAO1 and the $\Delta prpC$ mutant. An equal volume of H₂O was added to the control PAO1 and $\Delta prpC$ mutant cultures (also grown in triplicate). The cultures were harvested 2 h after the propionate addition, corresponding to an OD₆₀₀ of $\cong$ 0.6 (exponential growth) and RNA-seq analysis was carried out.

B; The panel shows a volcano plot illustrating the log₂-fold change in transcript abundance versus adjusted *p*-values for wild-type PAO1 grown in MOPS-succinate versus wild-type

PAO1 grown in MOPS-succinate + 500 μ M propionate. Transcripts which are significantly (q-val < 0.05) increased (red) or decreased (blue) in abundance are indicated. Selected transcripts are labelled.

C; Western blot showing protein expression levels of PrpB (32.1 kDa) in PAO1, and in the $\Delta prpC$ mutant, the $\Delta gltA_EVOL$ mutant, and the $\Delta prpR$ mutant after exposure to 4 mM propionate (+P) for 3 h. Isocitrate dehydrogenase (ICD – 45.6 kDa) served as loading control. Note that the $\Delta gltA_EVOL$ and $\Delta prpR$ mutants display constitutively active PrpB expression, independent of propionate addition. Data representative of three independent experiments.

D; Growth of $\Delta gltA$ and $\Delta gltA_EVOL1-3$ mutants compared with PAO1 in MOPS-acetate medium. The data are representative of three independent experiments, each performed in triplicate.

E; AlphaFold model of PrpR with the locations of the residues mutated and/or deleted in the $\Delta gltA_EVOL_1-3$ mutants highlighted. The winged helix-turn-helix (wHTH) motif and the GntR family FadR C-terminal domain (FCD) are shown.

Figure 7; Model for the operation of the 2MCC in Pa.

A; During growth in the absence of propionate or propionyl-CoA generating substrates, the 2MCC operon (*prp*) expression is repressed through the binding of PrpR to its upstream promoter region. Incomplete repression of the operon (from basal cellular propionyl-CoA or competing transcriptional activators) results in a basal, low level of *prpC* transcription.

B; As the cellular propionyl-CoA levels rise, this metabolite is condensed with oxaloacetate by PrpC, resulting in the formation of 2-MC. 2-MC likely then binds to PrpR, inducing conformational changes which lead to the dissociation of PrpR from the DNA. This de-represses the *prp* operon, allowing expression of the 2MCC enzymes. However, as the concentration of propionyl-CoA falls (due to depletion of propionate or BCAAs due to 2MCC activity) so too does the concentration of 2-MC, which, in turn, leads to re-binding of PrpR to the *prp* promoter region and a resumption in *prp* operon repression.

C; In the absence of citrate synthase (GltA), Pa can survive because of the low-level basal expression of PrpC; a promiscuous enzyme that also has citrate synthase activity. However, this low total citrate synthase activity is unable to meet cellular demand, resulting in a severe growth defect and a strong selection pressure to acquire mutations that increase *prpC* expression. Based on our work, it seems that mutations in *prpR* which abolish its repressor activity are the most commonly-selected mechanism for achieving this. These mutations lead to constitutive expression of the *prp* genes, and thus, an increase total cellular citrate synthase activity (compensating for the loss of GltA activity).





Figure 1; Proteomic analysis of Pa grown on Succinate and Propionate

A; Schematic depicting the Pa 2-methylcitrate cycle (2MCC) in Pa central carbon metabolism. The Pa central metabolic network shown here consists of six main blocks, designated with different colours: (i) the Embden-Meyerhoff-Parnas pathway (EMP, orange); (ii) the pentose phosphate pathway (PPP, green); (iii) the Entner-Doudoroff pathway (EDP, purple); (iv) the tricarboxylic acid cycle (TCA, blue) and glyoxylate shunt (red); (v) anaplerotic and gluconeogenic reactions (yellow), and (vi) the 2MCC (pink). The 2MCC operon arrangement (inset – grey underline) consists of genes which encode; a transcriptional regulator (designated here as *prpR*) which is thought to encode a ligand-responsive repressor, a methylcitrate synthase (*prpC*) which condenses propionyl-CoA (PrCoA) with oxaloacetate (OAA) to form 2-methylcitrate (2-MC), a 2-methylcitrate dehydratase/hydratase (*prpD*) which dehydrates 2-MC to yield 2-methylaconitate (2-MCA), a 2-methylcitrate dehydratase (*acnD*) and 2-methylaconitate cis-trans isomerase (*prpF*) which provide an alternative route for the generation of 2-MCA from 2-MC, and a 2-methylisocitrate lyase (*prpB*), which cleaves 2-methylisocitrate (2-MIC) to yield pyruvate (PYR) and succinate (SUC). Note that the 2-MCA generated in the PrpD or AcnD/PrpF reactions is rehydrated by an unlinked aconitase (likely AcnB in Pa) to yield the PrpB substrate, 2-MIC. Also, the enzyme responsible for the initial activation of propionate to yield PrCoA has not yet been identified for Pa, although in other organisms this function is carried out by a dedicated propionyl-CoA synthase (PrpE), or by acetyl-CoA synthase (AcsA), or by a combination of phosphotransacetylase (Pta) and acetate kinase (AckA) activities. Other abbreviations; AcCoA, acetyl-coenzyme A; CIT, citrate; ICIT, isocitrate; AKG, α -ketoglutarate; FUM, fumarate; MAL, malate; KDPG, 2-keto-3-deoxy-6-phosphogluconate; G3P, glyceraldehyde 3-phosphate; FBP, fructose 1,6-bisphosphate; F6P, fructose 6-phosphate; G6P, glucose 6-phosphate; 6PG, 6-phosphogluconate; Ri5P, ribulose 5-phosphate; R5P, ribose 5-phosphate; X5P, xylulose 5-phosphate; S7P, sedoheptulose 7-phosphate; E4P, erythrose 4-phosphate; PEP, phosphoenolpyruvate.

B; Illustration of the statistically significant proteomic changes ($p\text{-value} \leq 0.05$, fold change ≥ 1 or ≤ -1) during growth on propionate or succinate, as represented by Voronoi tessellations. Pathway assignment was performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) dataset. Proteome alterations which could not be assigned to a specific pathway (uncharacterised/hypothetical proteins) are shown as 'Not Mapped'. The specific protein identities for the protein clusters that were up-regulated during growth on propionate are shown in Figure S1A and statistical analyses of these data are illustrated in Figures S1B-D. The complete proteomics dataset is presented in File S1.






Figure 3; The Pa ORF (*prpC*) encoding 2-methylcitrate synthase is essential for growth on propionate. **A;** Wild-type Pa (PAO1), and the $\Delta acsA$, $\Delta aceA$ and $\Delta prpC$ mutants all grow comparably on MOPS agar containing glucose or succinate as a sole carbon source. $\Delta acsA$ has a growth defect during growth on MOPS-acetate and MOPS-propionate. $\Delta prpC$ cannot grow on MOPS propionate. The plates were photographed after 24 h incubation. **B;** Wild-type PAO1 and the $\Delta acsA$, $\Delta aceA$ and $\Delta prpC$ mutants were cultured on LB agar containing an increasing concentration of propionate (0, 5, 10, 20 mM, as indicated). The $\Delta prpC$ displays a pronounced growth defect in the presence of propionate concentrations > 10 mM. The plates were photographed after 24 h incubation. **C;** Intracellular propionyl-CoA concentration in wild-type Pa (PAO1) and in the $\Delta prpC$ mutant following 3h exposure to propionate (5 mM). Unpaired t-test with Welch's correction $p = 0.0026$. The experiment was performed using biological triplicates. **D;** Illustration of the interwoven reactions for propionate and acetate activation in Pa, feeding into the 2-methylcitrate cycle and TCA cycle, respectively. Following uptake, acetate and propionate are activated by AcsA. The resulting propionyl-CoA (PrCoA) is condensed with oxaloacetate (OAA) in a PrpC-catalyzed reaction to form 2-methylcitrate (2-MC), whereas the acetyl-CoA (AcCoA) is condensed with oxaloacetate in a GltA-catalyzed reaction to form citrate (CIT). **E;** Growth of the Pa glyoxylate shunt mutants $\Delta aceA$ and $\Delta gltB$ is blocked on MOPS agar plates containing a combination of high acetate concentration (40 mM) and low propionate concentration (5 mM) as the carbon source. However, this growth inhibition is partially overcome by increasing the propionate concentration to 20 mM (left to right in the figure). The plates were photographed after 48 h growth. The data are representative of two independent experiments, each performed in triplicate.




Figure 4; Biochemical and structural analysis of PrpC and GltA from Pa.

A. A Δ gltA mutant exhibits a growth defect when cultured on LB-agar, whereas a Δ prpC mutant displays a wild-type colony morphotype. The plates were photographed after 48 h. The data are representative of two independent experiments, each performed in triplicate.

B. Purified PrpC_{Pa} exhibits both citrate synthase activity (with acetyl-CoA as a substrate) and 2-methylcitrate synthase activity (with propionyl-CoA as a substrate). The concentration of OAA in each reaction was fixed at 0.5 mM. The data are representative of two independent experiments, each performed in triplicate.

C. Purified GltA_{Pa} is a citrate synthase with no detectable 2-methylcitrate synthase activity. The concentration of OAA was fixed at 0.5 mM. The data are representative of two independent experiments, each performed in triplicate.

D. The x-ray crystal structure of PrpC_{Pa} (PDB: 6S6F). PrpC_{Pa} is a homodimer. In the ribbon diagram shown, the protomers are coloured blue and grey.

E. Cartoon representation of the GltA_{Pa} hexamer in the asymmetric unit (left) and, for comparison with PrpC_{Pa}, the extracted GltA_{Pa} dimers (middle and right).

F. Superposition of the PrpC_{Pa} and GltA_{Pa} structures. PrpC_{Pa} and GltA_{Pa} share similar core α -helical folds (shown in grey to highlight similarities). However, GltA_{Pa} has an additional antiparallel β -sheet at its N-terminus (coloured in red to showcase differences).




Figure 5; Structural analysis of oxaloacetate-bound PrpCPa .

A; Crystal structure of oxaloacetate-bound PrpC_{Pa} represented in cartoon (PDB: 6S87). One protomer is coloured blue and the other orange. A 90° rotation about the X-axis is shown (right). Oxaloacetate is shown as green and red spheres.

B; Oxaloacetate binding site from *P. aeruginosa* PrpC chain D. Water molecules are shown in cyan spheres. Chain D and chain C residues are shown in orange and cyan, respectively. The electron density map (2Fo-Fc) in white is contoured at 1.5σ.

C; Superposition of the PrpC_{Pa} (white), GltA_{Pa} (pink) and *A. fumigatus* PrpC (5UQR) (green) oxaloacetate binding site. Oxaloacetate is shown in orange spheres. Most of the amino acid residues forming this site are conserved, except R307 (GltA_{Pa} numbering)

D; The left-hand panel shows the open (red) apo-conformation of PrpC_{Pa}, the middle panel shows the partially closed (blue) holo-conformation of PrpC_{Pa}, and the right hand panel shows a superposition of both conformations of PrpC_{Pa}. Note the structural rearrangement in the oxaloacetate-bound PrpC_{Pa} protomer (indicated by the red arrow).




Figure 6; RNA-seq analysis uncovers that propionate exposure induces expression of the *prp* operon and of the genes associated with branched chain amino acid catabolism in *Pa*. **A;** Schematic of the experimental design. At OD 0.2, 500 μ M sodium propionate was spiked into (triplicate) cultures of PAO1 and the $\Delta prpC$ mutant. An equal volume of H_2O was added to the control PAO1 and $\Delta prpC$ mutant cultures (also grown in triplicate). The cultures were harvested 2 h after the propionate addition, corresponding to an OD600 of 0.6 (exponential growth) and RNA-seq analysis was carried out. **B;** The panel shows a volcano plot illustrating the log2-fold change in transcript abundance versus adjusted p-values for wild-type PAO1 grown in MOPS-succinate versus wild-type PAO1 grown in MOPS-succinate + 500 μ M propionate. Transcripts which are significantly ($q\text{-val} < 0.05$) increased (red) or decreased (blue) in abundance are indicated. Selected transcripts are labelled. **C;** Western blot showing protein expression levels of PrpB (32.1 kDa) in PAO1, and in the $\Delta prpC$ mutant, the $\Delta gltA_EVOL$ mutant, and the $\Delta prpR$ mutant after exposure to 4 mM propionate (+P) for 3 h. Isocitrate dehydrogenase (ICD – 45.6 kDa) served as loading control. Note that the $\Delta gltA_EVOL$ and $\Delta prpR$ mutants display constitutively active PrpB expression, independent of propionate addition. Data representative of three independent experiments. **D;** Growth of $\Delta gltA$ and $\Delta gltA_EVOL1-3$ mutants compared with PAO1 in MOPS-acetate medium. The data are representative of three independent experiments, each performed in triplicate. **E;** AlphaFold model of PrpR with the locations of the residues mutated and/or deleted in the $\Delta gltA_EVOL_1-3$ mutants highlighted. The winged helix-turn-helix (wHTH) motif and the GntR family FadR C-terminal domain (FCD) are shown.




A.**INACTIVE 2MCC****B.****ACTIVE 2MCC****C.****GltA MUTANT**

Figure 7; Model for the operation of the 2MCC in Pa.

A; During growth in the absence of propionate or propionyl-CoA generating substrates, the 2MCC operon (*prp*) expression is repressed through the binding of PrpR to its upstream promoter region. Incomplete repression of the operon (from basal cellular propionyl-CoA or competing transcriptional activators) results in a basal, low level of *prpC* transcription.

B; As the cellular propionyl-CoA levels rise, this metabolite is condensed with oxaloacetate by PrpC, resulting in the formation of 2-MC. 2-MC likely then binds to PrpR, inducing conformational changes which lead to the dissociation of PrpR from the DNA. This de-represses the *prp* operon, allowing expression of the 2MCC enzymes. However, as the concentration of propionyl-CoA falls (due to depletion of propionate or BCAAs due to 2MCC activity) so too does the concentration of 2-MC, which, in turn, leads to re-binding of PrpR to the *prp* promoter region and a resumption in *prp* operon repression.

C; In the absence of citrate synthase (GltA), Pa can survive because of the low-level basal expression of PrpC; a promiscuous enzyme that also has citrate synthase activity. However, this low total citrate synthase activity is unable to meet cellular demand, resulting in a severe growth defect and a strong selection pressure to acquire mutations that increase *prpC* expression. Based on our work, it seems that mutations in *prpR* which abolish its repressor activity are the most commonly-selected mechanism for achieving this. These mutations lead to constitutive expression of the *prp* genes, and thus, an increase total cellular citrate synthase activity (compensating for the loss of GltA activity).